

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
7 February 2002 (07.02.2002)

PCT

(10) International Publication Number  
**WO 02/10146 A1**

(51) International Patent Classification<sup>7</sup>: **C07D 295/08**,  
295/14, 295/12, C07C 233/75, 235/42, A61K 31/165,  
31/395, 31/381, A61P 5/48, C07C 235/42, 235/48, 237/40,  
C07D 271/06, 231/12, 213/56

(21) International Application Number: **PCT/EP01/08637**

(22) International Filing Date: **26 July 2001 (26.07.2001)**

(25) Filing Language: **English**

(26) Publication Language: **English**

(30) Priority Data:  
0018758.3 31 July 2000 (31.07.2000) GB  
0112544.2 23 May 2001 (23.05.2001) GB

(71) Applicant (for all designated States except US):  
**SMITHKLINE BEECHAM P.L.C.** [GB/GB]; New  
Horizons Court, Brentford, Middlesex TW8 9EP (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **JOHNSON,**  
**Christopher, Norbert** [GB/GB]; GlaxoSmithKline Phar-  
maceuticals, New Frontiers Science Park South, Third  
Avenue, Harlow, Essex CM19 5AW (GB). **JONES,**  
**Martin** [GB/GB]; GlaxoSmithKline Pharmaceuticals,  
New Frontiers Science Park South, Third Avenue, Harlow,

Essex CM19 5AW (GB). **O'TOOLE, Catherine, Anne**  
[GB/GB]; GlaxoSmithKline Pharmaceuticals, New Fron-  
tiers Science Park South, Third Avenue, Harlow, Essex  
CM19 5AW (GB). **STEMP, Geoffrey** [GB/GB]; Glaxo-  
SmithKline Pharmaceuticals, New Frontiers Science Park  
South, Third Avenue, Harlow, Essex CM19 5AW (GB).  
**THEWLIS, Kevin, Michael** [GB/GB]; GlaxoSmithKline  
Pharmaceuticals, New Frontiers Science Park South,  
Third Avenue, Harlow, Essex CM19 5AW (GB). **WITTY,**  
**David** [GB/GB]; GlaxoSmithKline Pharmaceuticals, New  
Frontiers Science Park South, Third Avenue, Harlow,  
Essex CM19 5AW (GB).


(74) Agent: **RUTTER, Keith**; Corporate Intellectual Property,  
GlaxoSmithKline, Two New Horizons Court, Brentford,  
Middlesex TW8 9EP (GB).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,  
SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA,  
ZW.


(84) Designated States (regional): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian  
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European

[Continued on next page]

(54) Title: **CARBOXAMIDE COMPOUNDS AND THEIR USE AS ANTAGONISTS OF A HUMAN 11CBY RECEPTOR**



(I)



(a)

(57) Abstract: Compounds of formula (I) in which: each A is independently hydrogen, C<sub>1-6</sub>alkyl optionally substituted by hydroxyl, C<sub>1-6</sub>alkoxy, C<sub>1-6</sub>alkenyl or C<sub>1-6</sub>acyl group or a halogen atom or hydroxyl, CN or CF<sub>3</sub> group; R<sub>3</sub> is hydrogen, methyl or ethyl; R<sub>4</sub> is an optionally substituted aromatic carbocyclic or heterocyclic ring; Z is an O or S atom, or an NH or CH<sub>2</sub> group, or a single bond, at the 3 or 4 position of R<sub>4</sub> relative to the carbonyl group; R<sub>5</sub> is an optionally substituted aromatic carbocyclic or heterocyclic ring, or an optionally substituted, saturated or unsaturated, carbocyclic or heterocyclic ring; and Q is (a) Where X, Y, R<sub>1</sub> and R<sub>2</sub> are as defined in claim 1; are antagonists of a human 11CBY receptor.



patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

**Published:**

— *with international search report*

## CARBOXAMIDE COMPOUNDS AND THEIR USE AS ANTAGONISTS OF A HUMAN 11CBY RECEPTOR

This invention relates to a method of treatment using an antagonist of the human 11CBY receptor; a new therapeutic use of a class of carboxamide compounds which are  
5 antagonists to a human 11CBY receptor; also to novel compounds within that class, and to methods for making the compounds.

International Patent Application Publication Number WO 01/21577 (Takeda Chemical Industries Ltd.) discloses certain bisaryl compounds as melanin concentrating hormone  
10 antagonists.

WO 98/00401 (Merck & Co. Inc.) discloses benzamide derivatives as fibrinogen receptor antagonist prodrugs.

15 European Patent EP 0 358 118 (Boehringer Mannheim GmbH) discloses certain bisaryl compounds as inhibitors of erythrocyte aggregation and useful in the treatment of cardiac and circulatory disease.

European Patent Application EP 0 968 999 (Mitsui Chemical Inc.) discloses certain  
20 anilide derivatives useful in the treatment of arrhythmia.


WO 99/01127 (SmithKline Beecham) discloses certain *N*-[(amino alkoxy)phenyl] benzamides that are active as CCR5 receptor ligands, including the compounds  
*N*-[4-[2-[bis(1-methylethyl)amino]ethoxy]-2-fluorophenyl]-[1,1'-biphenyl]-4-  
25 carboxamide and *N*-[4-[2-[bis(1-methylethyl)amino]-ethoxy]-phenyl]-[1,1'-biphenyl]-4-carboxamide. Also WO 99/06146 (SmithKline Beecham) discloses certain substituted anilides that are antagonists of the CCR5 receptor, including the compounds:  
biphenyl-4-carboxylic acid [4-(2-dimethylamino-ethoxy)-phenyl]-amide,  
biphenyl-4-carboxylic acid [4-(2-diisopropylamino-ethoxy)-phenyl]-amide,  
30 *N*-[4-(2-diisopropylamino-ethoxy)-phenyl]-4-phenoxy-benzamide,  
*N*-[4-(2-diethylamino-ethoxy)-phenyl]-4-phenoxy-benzamide,  
*N*-[4-(2-diisopropylamino-ethoxy)-phenyl]-3-phenoxy-benzamide,  
*N*-[4-(2-diethylamino-ethoxy)-phenyl]-3-phenoxy-benzamide,

- 4-cyclohexyl-*N*-[4-(2-diisopropylamino-ethoxy)-phenyl]-benzamide,  
 4-cyclohexyl-*N*-[4-(2-diethylamino-ethoxy)-phenyl]-benzamide,  
 4-benzyl-*N*-[4-(2-diisopropylamino-ethoxy)-phenyl]-benzamide,  
 4-benzyl-*N*-[4-(2-diethylamino-ethoxy)-phenyl]-benzamide,  
 5 4'-ethyl-biphenyl-4-carboxylic acid [4-(2-diisopropylamino-ethoxy)-phenyl]-amide,  
 and 4'-ethyl-biphenyl-4-carboxylic acid [4-(2-diethylamino-ethoxy)-phenyl]-amide.

The present invention is based on the finding that a class of carboxamides overlapping with the above-mentioned benzamides and anilides, are, surprisingly, antagonists of a human 11CBy receptor disclosed in Nature, 400, 261-265 (1999).

Accordingly these compounds are believed to have a role in preventing, ameliorating or correcting dysfunctions or diseases, including, but not limited to, infections such as bacterial, fungal, protozoan and viral infections, particularly infection caused by HIV-1 or HIV-2; pain; cancers; diabetes; obesity; feeding and drinking abnormalities, such as anorexia and bulimia; asthma; Parkinson's disease; both acute and congestive heart failure; hypotension; hypertension; urinary retention; osteoporosis; angina pectoris; myocardial infarction; ulcers; allergies; benign prostatic hypertrophy; psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia or severe mental retardation; and dyskinesias, such as Huntington's disease or Gilles de la Tourette's syndrome, among others, hereinafter referred to as "the Disorders".

According to the present invention there is provided a method of treating the Disorders which comprises administering to a mammal suffering from one or more of the Disorders an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, in which:



each A is independently hydrogen, a C<sub>1-6</sub> alkyl optionally substituted by hydroxyl, C<sub>1-6</sub> alkoxy, C<sub>1-6</sub> alkenyl or C<sub>1-6</sub> acyl group or a halogen atom or hydroxyl, CN or CF<sub>3</sub> group; R<sub>3</sub> is hydrogen, methyl or ethyl.

Preferably R<sub>3</sub> is methyl.

- 5 R<sub>4</sub> is an optionally substituted aromatic carbocyclic or heterocyclic ring.


Z is an O or S atom, or an NH or CH<sub>2</sub> group, or a single bond, at the 3 or 4 position of R<sub>4</sub> relative to the carbonyl group.

Preferably, Z is a bond.

More preferably, Z is a bond at the 4-position of R<sub>4</sub> relative to the carbonyl group.

- 10 R<sub>5</sub> is an optionally substituted aromatic carbocyclic or heterocyclic ring, or an optionally substituted, saturated or unsaturated, carbocyclic or heterocyclic ring.

Preferably, R<sub>5</sub> is a phenyl ring.



- 20 (a) where X is an O or S atom, preferably an O atom;

Y is a linear or branched C<sub>2-4</sub> alkylene group, preferably a C<sub>3</sub> alkylene group, optionally substituted by a hydroxyl group, or is a C<sub>5-6</sub> cycloalkylene group,

R<sub>1</sub> and R<sub>2</sub> are independently a linear or branched C<sub>1-6</sub> alkyl, preferably ethyl; phenyl C<sub>1-6</sub> alkyl group; or

- 25 (b) where X is an O or S atom;

Y is a linear or branched C<sub>2-4</sub> alkylene group, optionally substituted by a hydroxyl group,

R<sub>1</sub> and R<sub>2</sub> are linked to form a 5, 6 or 7-membered ring, preferably a 5-membered ring, optionally containing one or more further heteroatoms selected from O, S or N, where N or C ring atoms are optionally substituted by Ra, -CO-Ra, -CO-NH-Ra, or CO-O-Ra,

- 30 where Ra is a linear or branched C<sub>1-6</sub> alkyl or aryl group; and the 5, 6 or 7-membered ring is optionally fused to an optionally substituted benzene ring, or a ring atom of the 5, 6 or 7-membered ring is optionally linked by a single bond or methylene group to Y; or

(c) where X is an O or S atom,

Y is a C<sub>2-4</sub> alkylene group, R1 is a C<sub>2-4</sub> alkylene group linked to Y to form a 5 or 6 membered ring and R2 is a linear or branched C<sub>1-6</sub> alkyl group; or

(d) where X is a N atom,

Y is a C<sub>2-4</sub> alkylene group, R1 is a C<sub>2-4</sub> alkylene group linked to X to form a 5 or 6 membered ring and R2 is a linear or branched C<sub>1-6</sub> alkyl group.

Alkyl groups, including alkyl groups that are part of alkoxy, acyl, etc groups, typically contain 1 to 6 carbon atoms, and may be linear or branched, such as methyl, ethyl, isopropyl and t-butyl, and optionally substituted by hydroxyl. Aryl groups are typically phenyl, but may include bicyclic groups such as naphthyl. Cycloalkyl groups typically contain from 3 to 7 carbon atoms. Heterocyclic groups may be monocyclic 5 to 7 membered rings containing up to three hetero atoms, such as pyridyl or imidazole, or bicyclic, especially heterocyclic rings fused to benzene rings, such as benzoxazole or benzimidazole. Aryl, cycloalkyl and heterocyclic groups may be optionally substituted by up to three substituents, which may suitably be selected from aryl, alkyl, alkoxy, halogen, hydroxy and cyano, or by linked substituents such as dioxymethylene.

Suitable aromatic rings for use as R4 include phenyl, pyridyl, thienyl, furanyl and pyrazolyl. Suitable optional substituents for R4 include halogen, CF<sub>3</sub>, C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkoxy. R4 may have 2 or 3 substituents, but preferably has only 1 substituent in addition to Z, or more preferably is unsubstituted apart from Z. Particularly suitable substituents for R4 include chloro, fluoro, trifluoromethyl, methyl, methoxy.

R5 may be monocyclic, for example thienyl, furanyl, imidazolyl, oxadiazolyl, phenyl, pyridinyl, cyclohexyl, piperidinyl, piperazinyl, pyrazinyl, pyrimidinyl; or a fused bicyclic ring system, for example naphthyl, 3,4-dioxymethylene-phenyl, benzofuranyl, indolyl; or a bicyclic system in which a monocyclic ring has a cyclic substituent such as oxadiazolyl, benzyloxy. Suitable optional substituents for R5 include halogen, CF<sub>3</sub>, CF<sub>3</sub>O, CHF<sub>2</sub>O, CN, amino, mono- or di-C<sub>1-6</sub> alkylamino, C<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkoxy, C<sub>1-6</sub> acyl, C<sub>1-6</sub> alkyl-S-, C<sub>1-6</sub> alkyl-SO<sub>2</sub>-, C<sub>1-6</sub> alkenyl, phenyl-C<sub>1-6</sub> alkyl, phenyl-C<sub>1-6</sub> alkoxy. R5 may have 2 or 3 substituents, but preferably has only 1 substituent, especially in the para position relative to Z. Particularly suitable substituents for R5 include chloro, fluoro,

trifluoromethyl, cyano, amino, methyl, ethyl, t-butyl, methoxy, acetyl, formyl, methylthio, methanesulphonyl, vinyl, benzyl, benzyloxy, hydrogen.

As for the ring substituents A, all A substituents may be hydrogen, but it is advantageous  
5 that no more than 3 are hydrogen. Suitable A substituents include halogen, C<sub>1-6</sub> alkyl optionally substituted with hydroxy, C<sub>1-6</sub> alkoxy, C<sub>1-6</sub> acyl and C<sub>1-6</sub> alkenyl.

Particularly suitable A substituents include C1-2alkoxy, C1-2alkyl, C1-2 acyl. Preferable substituents for A include chloro, fluoro, methyl, ethyl, hydroxyethyl, methoxy, formyl, acetyl, vinyl and allyl. More preferable substituents for A include methoxy.

10 Suitably, the A substituent is adjacent to the group Q.

In the system Q, in configuration (a) particularly suitable substituents for R1 and R2 include methyl, ethyl, isopropyl, benzyl, phenethyl. Y may especially be -(CH<sub>2</sub>)<sub>2</sub>-, -(CH<sub>2</sub>)<sub>3</sub>-, -(CH<sub>2</sub>)<sub>4</sub>-, -CH<sub>2</sub>-CH(CH<sub>3</sub>)-CH<sub>2</sub>-. When Y is substituted by hydroxy, it may be  
15 for example -CH<sub>2</sub>-CH(OH)-CH<sub>2</sub>-.


In configuration (b) of system Q, the ring formed by linking R1 and R2 may be pyrrolidinyl, piperidinyl, azepanyl, or imidazolyl. Fused rings include indolinyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl and benzoazepinyl. When a second  
20 heteroatom is present, suitable rings include thiazinyl, oxazinyl and piperazinyl. A second N atom may be substituted, for example by phenyl, methyl, ethyl, isopropyl or acetyl. Y is typically -(CH<sub>2</sub>)<sub>2</sub>-. The ring may be linked back to Y to form a quinuclidinyl group.

25 In configuration (c) of system Q, the ring formed by linking R1 to Y may be a pyrrolidinyl or piperidinyl ring. The linkage to Y may be such as to create a ring linked by a single bond from a ring carbon atom directly to X or via a methylene or ethylene linking group. R2 is typically methyl so that the N atom of the ring is substituted by methyl.

30


In configuration (d) of system Q, the ring formed by linking R1 to N is suitably a 5 or 6-membered ring such as diazinyl or piperazinyl. Y is typically  $-(CH_2)_2-$ . R2 is typically methyl so that the second N atom (other than X) of the ring is substituted by methyl.

- 5 Within the scope of formula (I) is a class of compounds of general formula (II)




- where A = H and OMe, R3 = H, X = O, Y =  $CH_2CH_2$ , Z = a bond, R4 = Ph, R5 is either meta or para substituted on R4, and R1, R2 and R5 are as defined for formula (I).
- 10

Also within the scope of formula (I) is a class of compounds of general formula (III)



- 15 where A = H and OMe, R3 = H, X = O, Y =  $CH_2-CH_2$ , Z = O,  $CH_2$  or NH and is either meta or para substituted on R4, R4 = Ph, R5 is Ph, and R1 and R2 are as defined for formula (I).

Also within the scope of formula (I) is a class of compounds of general formula (IV)




20



(IV)

where A = H and OMe, R1 = R2 = *i*Pr, R3 = H, X = O, Y = CH<sub>2</sub>-CH<sub>2</sub>, and R4 and R5 are substituted phenyl or heterocycles as defined for formula (I)

- 5 Also within the scope of formula (I) is a class of compounds of general formula (V)




(V)

where R3 = H, X = O, Y = CH<sub>2</sub>-CH<sub>2</sub>, Z = O, CH<sub>2</sub>, NH or a bond, R4 = Ph, R5 is Ph or cyclohexyl (Cy), Z is either meta or para substituted on R4, and A (R6,R7) and R1,R2 are as defined in formula (I).

10


Also within the scope of formula (I) is a class of compounds of general formula (VI)



(VI)

- 15 where X = O, Y = CH<sub>2</sub>-CH<sub>2</sub>, R4 = phenyl, R5 = phenyl or cyclohexyl (Cy), Z = O, CH<sub>2</sub> or a bond, and A (R8,R9), R3 and R1,R2 are as defined in formula (I).

Also within the scope of formula (I) is a class of compounds of general formula (VII)




(VII)

where A = H and OMe, X = O, R3 = H, R4 = 3-pyridyl (with respect to the carbonyl group), R5 = phenyl, Z = a para bond, and R1, R2 are as defined in formula (I).

5

Also within the scope of formula (I) is a class of compounds of general formula (VIII)




(VIII)

where A = H and OMe, R3 = H, X = O, R4 = phenyl, Z = O, CH<sub>2</sub> or a bond, R5 = Ph or cyclohexyl (Cy), Y is a chain of 3 or 4 carbon atoms optionally substituted by an hydroxyl group, and R1, R2 are as defined in formula (I).

10

Also within the scope of formula (I) is a class of compounds of general formula (IX)



(IX)


where A = H and OMe, R3 = H, X = N, R4 = phenyl, Z = a para substituted bond, R5 = Ph or cyclohexyl (Cy), Y and R2 form a piperazinyl ring between X and N, and R1 is as defined in formula (I).

15

A preferred sub-class of compounds for use in the method of treatment of this invention are compounds of formula (I) in which R3 is methyl.

Within formula (I) is a novel group of compounds in which R3 is methyl or ethyl. The  
5 novel compounds, or a salt or solvate thereof, form a further aspect of this invention.

A particular group of novel compounds is a class of compounds of general formula (VI)



(VI)

10 where R8 and R9 are as defined for A in formula (I), R1, R2 and R5 are as defined in formula (I), and R3 is methyl or ethyl.

Suitably R5 is phenyl or cyclohexyl optionally substituted by halogen, haloalkyl, alkyl or alkoxy; Z is O, CH<sub>2</sub> or a single bond; R8 and R9 are independently selected from  
15 hydrogen, halogen, alkyl and alkoxy; R1 and R2 are alkyl or linked together to form a ring; and R3 is ethyl or methyl.

Another aspect of this invention is a class of novel compounds, or a salt or solvate thereof, which are the compounds of formula (I) excluding the compounds:

20 *N*-[4-[2-[bis(1-methylethyl)amino]ethoxy]-2-fluorophenyl]-[1,1'-biphenyl]-4-carboxamide,  
*N*-[4-[2-[bis(1-methylethyl)amino]ethoxy]phenyl]-[1,1'-biphenyl]-4-carboxamide,  
 biphenyl-4-carboxylic acid [4-(2-diisopropylamino-ethoxy)-phenyl]-amide,  
*N*-[4-(2-diisopropylamino-ethoxy)-phenyl]-4-phenoxy-benzamide,  
 25 *N*-[4-(2-diethylamino-ethoxy)-phenyl]-4-phenoxy-benzamide,  
*N*-[4-(2-diisopropylamino-ethoxy)-phenyl]-3-phenoxy-benzamide,  
*N*-[4-(2-diethylamino-ethoxy)-phenyl]-3-phenoxy-benzamide,  
 4-cyclohexyl-*N*-[4-(2-diisopropylamino-ethoxy)-phenyl]-benzamide,  
 4-cyclohexyl-*N*-[4-(2-diethylamino-ethoxy)-phenyl]-benzamide,

4-benzyl-N-[4-(2-diisopropylamino-ethoxy)-phenyl]-benzamide,  
4-benzyl-N-[4-(2-diethylamino-ethoxy)-phenyl]-benzamide,  
4'-ethyl-biphenyl-4-carboxylic acid [4-(2-diisopropylamino-ethoxy)-phenyl]-amide,  
and 4'-ethyl-biphenyl-4-carboxylic acid [4-(2-diethylamino-ethoxy)-phenyl]-amide.

5

A further aspect of this invention is those compounds of the Examples herein which are novel.

10 The compounds of formulae (I) to (IX), or their salts or solvates, are preferably in pharmaceutically acceptable or substantially pure form. By pharmaceutically acceptable form is meant, *inter alia*, of a pharmaceutically acceptable level of purity excluding normal pharmaceutical additives such as diluents and carriers, and including no material considered toxic at normal dosage levels.

15 Suitable salts and solvates include pharmaceutically acceptable salts and pharmaceutically acceptable solvates.

20 Suitable pharmaceutically acceptable salts include metal salts, such as for example aluminium, alkali metal salts such as lithium, sodium or potassium, alkaline earth metal salts such as calcium or magnesium and ammonium or substituted ammonium salts, for example those with lower alkylamines such as triethylamine, hydroxy alkylamines such as 2-hydroxyethylamine, bis-(2-hydroxyethyl)-amine or tri-(2-hydroxyethyl)-amine, cycloalkylamines such as bicyclohexylamine, or with procaine, dibenzylpiperidine, N-benzyl- $\beta$ -phenethylamine, dehydroabietylamine, N,N'-bisdehydroabietylamine,  
25 glucamine, N-methylglucamine or bases of the pyridine type such as pyridine, collidine, quinine or quinoline.

30 Suitable pharmaceutically acceptable salts also includes pharmaceutically acceptable acid addition salts, such as those provided by pharmaceutically acceptable inorganic acids or organic acids.

35 Suitable pharmaceutically acceptable acid addition salts provided by pharmaceutically acceptable inorganic acids includes the sulphate, nitrate, phosphate, borate, hydrochloride and hydrobromide and hydroiodide.

Suitable pharmaceutically acceptable acid addition salts provided by pharmaceutically acceptable organic acids includes the acetate, tartrate, maleate, fumarate, malonate,

citrate, succinate, lactate, oxalate, benzoate, ascorbate, methanesulphonate,  $\alpha$ -keto glutarate and  $\alpha$ -glycerophosphate.

Suitable pharmaceutically acceptable solvates include hydrates.

5

A substantially pure form will generally contain at least 50% (excluding normal pharmaceutical additives), preferably 75%, more preferably 90% and still more preferably 95% of the compound of formula (I) to (IX) or its salt or solvate.

- 10 One preferred pharmaceutically acceptable form is the crystalline form, including such form in a pharmaceutical composition. In the case of salts and solvates the additional ionic and solvent moieties must also be non-toxic.

- 15 Examples of pharmaceutically acceptable salts of a compound of formula (I) to (IX) include the acid addition salts with the conventional pharmaceutical acids, for example, maleic, hydrochloric, hydrobromic, phosphoric, acetic, fumaric, salicylic, citric, lactic, mandelic, tartaric, succinic, benzoic, ascorbic and methanesulphonic.

- 20 The compounds of formula (I) to (IX) may exist in more than one stereoisomeric form, and the invention extends to all such forms as well as to their mixtures thereof, including racemates.

- 25 The compounds of formula (I) to (IX), or salts or solvates thereof, may be prepared by the methods illustrated in the following general reaction schemes, or by modification thereof, using readily available starting materials, reagents and conventional synthetic procedures. If a particular enantiomer of a compound of the present invention is desired, it may be synthesised starting from the desired enantiomer of the starting material and performing reactions not involving racemization processes or it may be prepared by chiral synthesis, or by derivatisation with a chiral auxiliary, where the resulting diastereomeric mixture is 30 separated and the auxiliary group cleaved to provide the pure desired enantiomers. Alternatively, where the molecule contains a basic functional group, such as amino, or an acidic functional group, such as carboxy, diastereomeric salts are formed with an appropriate optically active acid or base, followed by resolution of diastereomeric salts by fractional crystallization and subsequent recovery of the pure enantiomers.

35

Compounds of formula (I) to (IX) may be prepared by condensing suitably substituted aryl or heteroarylcarboxylic acids and suitably substituted anilines, which are commercially


available or synthesized by methods known to the art from commercially available starting materials, using methods known to the art. For example, suitably substituted aryl or heteroarylcarboxylic acids are treated with an activating reagent, such as thionyl chloride, at a suitable temperature, such as at reflux, to afford aryl or heteroarylcarbonyl chlorides, and the aryl- or heteroarylcarbonyl chlorides are condensed with suitably substituted anilines in the presence of a suitable base, such as diisopropylethylamine, in a suitable solvent, such as dichloromethane, to give compounds of formula (I).

In particular, the preparation of certain carboxamides of formula (I) in which R<sub>3</sub> is H is disclosed in WO 99/01127 and WO 99/06146 mentioned above, and analogous methods of preparation may be used in the present invention. Many additional methods for converting a carboxylic acid to an amide are known, and can be found in standard reference books such as "Compendium of Organic Synthetic Methods", Vol. I-VI (published by Wiley-Interscience).

For example the compounds of formula (I) may be prepared by reacting a compound of formula (X)



where L is a leaving group such as halogen, especially chlorine or bromine with a compound of formula (XI)



(XI)

where A, Z, R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub> and Q are as defined for formula (I).

In this process, groups convertible to R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub> and R<sub>5</sub> may be present during the coupling, and converted to R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub> and R<sub>5</sub> after coupling. Also it may be convenient to convert one R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub> and R<sub>5</sub> to another R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub> and R<sub>5</sub> group after coupling. In particular, ring formation between the groups R<sub>1</sub>, X, Y, R<sub>2</sub> or

the addition of suitable cyclic groups embodying R1, X, Y, R2, may be performed after coupling.

Accordingly, there is provided a process for the preparation of a compound of formula (I), or a salt or solvate thereof, wherein R3 is methyl or ethyl which process comprises the reaction of a compound of formula (X) as hereinbefore defined with a compound of formula (XI) wherein A and Q are as hereinbefore defined and R3 is methyl or ethyl.


There therefore also provided a process for the preparation of a compound of formula (I), or a salt or solvate thereof, with the proviso that the following compounds are excluded;

*N*-[4-[2-[bis(1-methylethyl)amino]ethoxy]-2-fluorophenyl]-[1,1'-biphenyl]-4-carboxamide,  
*N*-[4-[2-[bis(1-methylethyl)amino]ethoxy]phenyl]-[1,1'-biphenyl]-4-carboxamide,  
biphenyl-4-carboxylic acid [4-(2-diisopropylamino-ethoxy)-phenyl]-amide,  
*N*-[4-(2-diisopropylamino-ethoxy)-phenyl]-4-phenoxy-benzamide,  
*N*-[4-(2-diethylamino-ethoxy)-phenyl]-4-phenoxy-benzamide,  
*N*-[4-(2-diisopropylamino-ethoxy)-phenyl]-3-phenoxy-benzamide,  
*N*-[4-(2-diethylamino-ethoxy)-phenyl]-3-phenoxy-benzamide,  
4-cyclohexyl-*N*-[4-(2-diisopropylamino-ethoxy)-phenyl]-benzamide,  
4-cyclohexyl-*N*-[4-(2-diethylamino-ethoxy)-phenyl]-benzamide,  
4-benzyl-*N*-[4-(2-diisopropylamino-ethoxy)-phenyl]-benzamide,  
4-benzyl-*N*-[4-(2-diethylamino-ethoxy)-phenyl]-benzamide,  
4'-ethyl-biphenyl-4-carboxylic acid [4-(2-diisopropylamino-ethoxy)-phenyl]-amide,  
and 4'-ethyl-biphenyl-4-carboxylic acid [4-(2-diethylamino-ethoxy)-phenyl]-amide.

which process comprises the reaction of a compound of formula (X) as hereinbefore defined with a compound of formula (XI) as hereinbefore defined.

The compounds of formula (XI) may be prepared in a number of ways, for example when X is O or S coupling an appropriately substituted nitrobenzene compound with a dialkylaminoalcohol or thiol, and converting the NO<sub>2</sub> group to NH<sub>2</sub> by hydrogenation in

the presence of palladium catalyst (or with iron/ammonium chloride) before coupling with an acid chloride, for example as illustrated below:



#### Procedure A51

Acid chlorides of formula (X) may be prepared from the corresponding acids which are commercially available or described in the literature or may be prepared by methods analogous to those of the literature.


Alternatively the acids of formula (X) may be prepared by combining moieties containing respectively R5 and R4 via Z.

10

This may also be achieved conveniently by first coupling a compound of R4-CO-L with the compound of formula (XI) followed by reaction with a compound R5-Z-L (or L-R4-CO-L with R5-Z). For example an amine of formula (XI) may be reacted with an appropriately substituted bromobenzoyl chloride which may be then reacted with, for example, an appropriately substituted phenyl moiety with a leaving group, or a cyclic amine, as in the following scheme:


15






BINAP = (S)-(+)-2,2'-Bis(diphenylphosphino)-1,1'-binaphthyl

Similar reactions building up the structure of formula (I) may be carried out starting with the compound of formula (X) and adding the equivalent of formula (XI) in sections, as in the scheme below where an *N*-protecting group on Q, here a piperazine ring, may be removed after coupling the components of formula (I) and replacement by a desired substituent:




In an alternative strategy for building up the compounds of formula (XI) before coupling, so as to introduce a hydroxy group in Y, an appropriately substituted nitrophenol is linked to an epoxy compound which is then reacted with an amine forming a group Q which is - O-Y(OH)-NR<sub>1</sub>R<sub>2</sub>, before coupling with R<sub>5</sub>-Z-R<sub>4</sub>-CO-L, as illustrated by:



Novel compounds of formula (I) where the amide nitrogen is alkylated (R3 is methyl or ethyl) may be prepared by alkylating an anilide of formula (XI) before coupling with an acid chloride of formula (X), for example, by utilising the following reductive amination

5 procedure:



The compounds of formula (I) may be converted into their pharmaceutically acceptable salts by reaction with the appropriate organic or mineral acids.

- 10 Solvates of the compounds of formula (I) may be formed by crystallization or recrystallization from the appropriate solvent. For example, hydrates may be formed by crystallization or recrystallization from aqueous solutions, or solutions in organic solvents containing water.

Also salts or solvates of the compounds of formula (I) which are not pharmaceutically acceptable may be useful as intermediates in the production of pharmaceutically acceptable salts or solvates. Accordingly such salts or solvates also form part of this invention.

5

The above-listed compounds and pharmaceutically acceptable salts thereof, especially the hydrochloride, and pharmaceutically acceptable solvates, especially hydrates, form a preferred aspect of the present invention.

10 By virtue of the activity of these compounds as antagonists of a human 11CBy receptor, the compounds of formula (I) are believed to have a role in preventing, ameliorating or correcting dysfunctions of diseases, including, but not limited to, "the Disorders" previously mentioned.

15 It is also considered that the treatment of certain of the Disorders mentioned above by an antagonist to the human 11CBy receptor are novel. Accordingly, the invention also provides a method for the treatment of diabetes, major depression, manic depression, anxiety, schizophrenia and sleep disorders, in human or non-human mammals which method comprises the administration of a therapeutically effective amount of an  
20 antagonist to the human 11CBy receptor. In particular the the invention provides a method for the treatment of diabetes in human or non-human mammals which method comprises the administration of a therapeutically effective amount of an antagonist to the human 11CBy receptor. In particular the invention provides a method for the treatment of major depression, in human or non-human mammals which method comprises the  
25 administration of a therapeutically effective amount of an antagonist to the human 11CBy receptor. In particular the invention provides a method for the treatment of manic depression, in human or non-human mammals which method comprises the administration of a therapeutically effective amount of an antagonist to the human 11CBy receptor. In particular the the invention provides a method for the treatment of  
30 anxiety in human or non-human mammals which method comprises the administration of a therapeutically effective amount of an antagonist to the human 11CBy receptor. In particular the the invention provides a method for the treatment of schizophrenia in human or non-human mammals which method comprises the administration of a therapeutically effective amount of an antagonist to the human 11CBy receptor.

In particular the the invention provides a method for the treatment of sleep disorders, in human or non-human mammals which method comprises the administration of a therapeutically effective amount of an antagonist to the human 11CBy receptor.

- 5 The administration of such compounds to a mammal may be by way of oral (including sub-lingual), parenteral, nasal, rectal or transdermal administration.

An amount effective to treat the Disorders hereinbefore described depends on the usual factors such as the nature and severity of the disorders being treated and the weight of the mammal. However, a unit dose will normally contain 1 to 1000 mg, suitably 1 to 500 mg, for example an amount in the range of from 2 to 400 mg such as 2, 5, 10, 20, 30, 40, 50, 100, 200, 300 and 400 mg of the active compound. Unit doses will normally be administered once or more than once per day, for example 1, 2, 3, 4, 5 or 6 times a day, more usually 1 to 4 times a day, such that the total daily dose is normally in the range, for a 70 kg adult of 1 to 1000 mg, for example 1 to 500 mg, that is in the range of approximately 0.01 to 15 mg/kg/day, more usually 0.1 to 6 mg/kg/day, for example 1 to 6 mg/kg/day.

- 20 It is greatly preferred that compounds of formula (I) are administered in the form of a unit-dose composition, such as a unit dose oral (including sub-lingual), nasal, rectal, topical or parenteral (especially intravenous) composition.

Such compositions are prepared by admixture and are suitably adapted for oral or parenteral administration, and as such may be in the form of tablets, capsules, oral liquid preparations, powders, granules, lozenges, reconstitutable powders, injectable and infusable solutions or suspensions or suppositories. Orally administrable compositions are preferred, in particular shaped oral compositions, since they are more convenient for general use.

- 30 Tablets and capsules for oral administration are usually presented in a unit dose, and contain conventional excipients such as binding agents, fillers, diluents, tableting agents, lubricants, disintegrants, colourants, flavourings, and wetting agents. The tablets may be coated according to well known methods in the art.

Suitable fillers for use include cellulose, mannitol, lactose and other similar agents. Suitable disintegrants include starch, polyvinylpyrrolidone and starch derivatives such as sodium starch glycolate. Suitable lubricants include, for example, magnesium stearate.

5    Suitable pharmaceutically acceptable wetting agents include sodium lauryl sulphate.

These solid oral compositions may be prepared by conventional methods of blending, filling, tableting or the like. Repeated blending operations may be used to distribute the active agent throughout those compositions employing large quantities of fillers. Such

10    operations are, of course, conventional in the art.

Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups, or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations

15    may contain conventional additives such as suspending agents, for example sorbitol, syrup, methyl cellulose, gelatin, hydroxyethylcellulose, carboxymethyl cellulose, aluminium stearate gel or hydrogenated edible fats; emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; non-aqueous vehicles (which may include edible oils), for example, almond oil, fractionated coconut oil, oily esters such as esters of

20    glycerine, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid; and if desired conventional flavouring or colouring agents.

Oral formulations also include conventional sustained release formulations, such as

25    tablets or granules having an enteric coating.

For parenteral administration, fluid unit dose forms are prepared containing the compound and a sterile vehicle. The compound, depending on the vehicle and the concentration, can be either suspended or dissolved. Parenteral solutions are normally

30    prepared by dissolving the compound in a vehicle and filter sterilising before filling into a suitable vial or ampoule and sealing. Advantageously, adjuvants such as a local anaesthetic, preservatives and buffering agents are also dissolved in the vehicle. To

enhance the stability, the composition can be frozen after filling into the vial and the water removed under vacuum.

5 Parenteral suspensions are prepared in substantially the same manner except that the compound is suspended in the vehicle instead of being dissolved and is sterilised by exposure to ethylene oxide before suspending in the sterile vehicle. Advantageously, a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound of the invention.

10 As is common practice, the compositions will usually be accompanied by written or printed directions for use in the medical treatment concerned.

Compounds of the present invention may be employed alone or in conjunction with other compounds, such as therapeutic compounds.

15 No adverse toxicological effects are expected for the compounds of the invention, when administered in accordance with the invention.

Accordingly, in a further aspect, the present invention provides a pharmaceutical  
20 composition for use in the treatment and/or prophylaxis of one or more of the Disorders which comprises a compound of this invention, or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier.

The present invention also provides a method of treatment and/or prophylaxis of one or  
25 more of the Disorders comprising administering to the sufferer in need thereof an effective or prophylactic amount of a compound of this invention, or a pharmaceutically acceptable salt or solvate thereof.

In a further aspect the invention provides the use of a compound of this invention, or a  
30 pharmaceutically acceptable salt or solvate thereof, for the manufacture of a medicament for the treatment and/or prophylaxis of one or more of the Disorders.

In a still further aspect the invention provides the use of a novel compound of this invention, or a pharmaceutically acceptable salt or solvate, thereof as a therapeutic agent, in particular for the treatment and/or prophylaxis of one or more of the Disorders.

- 5    Compounds for use in this invention and their preparation are illustrated in the following Examples and Tables.

These Examples illustrate general procedures and sources of chemicals utilised to prepare compounds whose structures are shown in the Tables of data which follow the Examples.

- 10   In the case of Examples prepared as members of a coupled array, the synthetic origin of all starting components of the array are shown in the Examples. Rather than detailing the experimental procedure for each case, the method by which individual members of the array were prepared is indicated in a Table by reference to a related Example. Mass spectral characterisation of all Examples is provided in the tables of data. Additional  
15   characterisation is provided for selected representative Examples with full experimental procedures.

**Example A1 [WO-00/06146]**

- Utilising the procedure of **Example A7** with 4-biphenylcarboxylic acid [Aldrich] in place  
20   of 2'-methyl-4-biphenylcarboxylic acid.

**Example A2**

- Correspondingly **Example A7** with 4-(5-methyl-[1,2,4]oxadiazol-3-yl)-benzoic acid  
[J.Org.Chem. 50; 8; 1985; 1182].

25

**Example A3**

Correspondingly **Example A7** with 4-pyrazol-1-yl-benzoic acid [Can.J.Chem.; 41; 1963; 1540].

30   **Example A4**

Correspondingly **Example A7** with 3-biphenylcarboxylic [Med.Chem.Res.; 6; 2; 1996].

**Example A5**

Correspondingly **Example A7** with 4-(2-pyridyl)-benzoic acid [J.Chem.Soc.; 1940; 355, 356].

#### **Example A6**

- 5 Correspondingly **Example A7** with 3'-acetyl-biphenyl-4-carboxylic acid [Patent WO-9743262].

#### **Example A7**

- 10 **2-methylphenyl-4-phenylcarboxylic acid [3-methoxy-4-(2-bis-(2-methylethyl)amino)-ethoxy)-phenyl amide.**

To a solution of the acid (2'-methyl-biphenyl-4-carboxylic acid) [Patent WO-9901127] (55mg, 0.26mmol) in dimethylformamide were added (1-(3-dimethylaminopropyl)-3-ethyl carbodiimide hydrochloride [Aldrich] (50mg, 0.26mmol) and 1-hydroxy-7-azabenzotriazole [Aldrich] (35mg, 0.26mmol) followed by diisopropylethylamine  
15 (0.04ml, 0.25mmol) and the aniline (4-(2-diisopropylamino-ethoxy)-3-methoxy-phenylamine) (69mg, 0.22mmol), [prepared using the method used to form 3-methoxy-4-(2-pyrrolidin-1-yl-ethoxy)-phenylamine in **Example A51** but with 2-diisopropylamino-ethanol in place of 1-(2-hydroxyethyl)-pyrrolidine]. The reaction mixture was stirred at room temperature for 16 hours. The solvent was evaporated, and the residue re-dissolved  
20 in dichloromethane (10ml), filtered through an SAX [Varian] column (2g), and the filtrate was then stirred with PS-isocyanate resin [Argonaut Technologies] (100mg, 0.38mmol) for 16 hours. The mixture was filtered, evaporated, and the residue purified by flash chromatography on silica gel using dichloromethane – aq. ammonia - methanol as eluent, to afford the title compound as an oil.

- 25 <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 1.04 (12H, d), 2.28 (3H, s), 2.90 (2H, t), 3.05 (2H, m), 3.91 (3H, s), 3.95 (2H, t), 6.88 (1H, d), 7.03 (1H, dd), 7.27-7.32 (4H, m), 7.44, (2H, d), 7.53 (1H, d), 7.94 (2H, d) and 8.01 (1H, bs); MS (AP+ve): m/z 461 [M+H]<sup>+</sup>.

#### **Example A8**

- 30 Utilising the procedure of **Example A7** with cyclohexyl-4-benzoic acid [Aldrich], in place of (2'-methyl-biphenyl-4-carboxylic acid).

#### **Example A9**



Correspondingly **Example A7** with 4-(2-thienyl)-benzoic acid [J.Chem.Soc.Perkin Trans.1; 17; 1992; 2203].

**Example A10**

- 5 Correspondingly **Example A7** with 4-(1-methyl-1*H*-pyrazol-4-yl)-benzoic acid [Patent:WO-9906409].

**Example A11**

- 10 Correspondingly **Example A7** with 4'-(5-methyl-[1,2,4]oxadiazol-3-yl)-biphenyl-4-carboxylic acid [Patent:WO -9743262].

**Example A12**

Correspondingly **Example A7** with 4-benzyl-carboxylic acid [Apin].

15 **Example A13**

Correspondingly **Example A7** with 3'-cyano-biphenyl-3-carboxylic acid [J.Chem.Soc.Perkin Trans.2; 1; 1984; 35-38].

**Example A14**

- 20 Correspondingly **Example A7** with 3'-methanesulfonyl-biphenyl-4-carboxylic acid [Izv.Sib.Otd.Akad.Nauk SSSR Ser.Khim.Nauk; 11; 1966; 62].

**Example A15**

- 25 Correspondingly **Example A7** with 3-thiophen-2-yl-benzoic acid [Tetrahedron Lett.; 39; 24; 1998; 4175].

**Example A16**

- Correspondingly **Example A7** with 3-thiophen-3-yl-benzoic acid [J.Chem.Soc.B; 1970; 1595].

30

**Example A17**

Correspondingly **Example A7** with 4-acetyl-4-biphenylcarboxylic acid [Aldrich].

**Example A18**

Correspondingly **Example A7** with 4'-cyano-3'-methylbiphenyl-4-carboxylic acid [WO-9850358].

5 **Example A19**

Correspondingly **Example A7** with 4'-(5-methyl-[1,3,4]oxadiazol-2-yl)-biphenyl-4-carboxylic acid [Patent:WO-9743262].

**Example A20**

10 Correspondingly **Example A7** with 4-thiophen-3-yl-benzoic acid [J.Chem.Soc.B; 1970; 1595].

**Example A21**

Correspondingly **Example A7** with 4-pyrazin-2-yl-benzoic acid [Patent WO-9854164].  
15

**Example A22**

Utilising the procedures of **Example A93** with 2-methoxyphenylboronic acid [Aldrich] in place of 4-methylphenylboronic acid, and **Example A51** with 2-(diisopropylamino)-ethanol in place of 1-(2-hydroxyethyl)-pyrrolidine .  
20

**Example A23**

Utilising the procedure of **Example A22** with 4-trifluoromethylphenylboronic acid [Aldrich], in place of 2-methoxyphenylboronic acid [Aldrich]

25 **Example A24**

Correspondingly **Example A23** with 3-aminophenylboronic acid [Aldrich].

**Example A25**

Correspondingly **Example A23** with 4-benzyloxyphenylboronic acid [Lancaster].  
30

**Example A26**

Correspondingly **Example A23** with 2-naphthylboronic acid [Lancaster].

**Example A27**

Correspondingly **Example A23** with 3-naphthylboronic acid [Lancaster].

5 **Example A28**

Correspondingly **Example A23** with 4-methylphenylboronic acid [Lancaster].

**Example A29**

Correspondingly **Example A23** with 4-methylthiophenylboronic acid [Lancaster].

10

**Example A30**

Correspondingly **Example A23** with 3-trifluoromethylphenylboronic acid [Lancaster].

**Example A31**15 

Correspondingly **Example A23** with 4-carbonylphenylboronic acid [Aldrich].

**Example A32**

Correspondingly **Example A23** with 3,4-(methylenedioxy)phenylboronic acid [Aldrich].

20 **Example A33**

Correspondingly **Example A23** with 4-vinylphenylboronic acid [Aldrich].

**Example A34**

Correspondingly **Example A23** with 3-methoxyphenylboronic acid [Lancaster].

25

**Example A35**

Utilising the procedure of **Example A51** with 1-(2-hydroxyethyl)morpholine [Aldrich] in place of 1-(2-hydroxyethyl)pyrrolidine.

30 **Example A36**

Utilising the procedure of **Example A35** with 4-cyclohexylbenzoic acid [Aldrich]. in place of 4-biphenylcarboxylic acid.

**Example A37**

Utilising the procedure of **Example A51** with 2-dimethylaminoethanol [Aldrich], in place of 1-(2-hydroxyethyl)pyrrolidine.

5

**Example A39**

Correspondingly **Example A51** with (R)-(+)-1-methyl-2-pyrrolidinemethanol (Patent WO-9932480).

10 **Example A41**

Correspondingly **Example A51** with 3-hydroxy-1-methylpiperidine [Aldrich].

**Example A43**

Correspondingly **Example A51** with 2-dimethylamino-1-propanol [ICN-RF].

15

**Example A45**

Correspondingly **Example A51** with 2-(diethylamino)-ethanol [Aldrich].

**Example A47**

20 Correspondingly **Example A51** with (S)-(-)-1-methyl-2-pyrrolidinemethanol [Aldrich].

**Example A49**

Correspondingly **Example A51** with *N*-benzyl-*N*-methylethanolamine [Aldrich].

25 **Example A51**

**Biphenyl-4-carboxylic acid [3-methoxy-4-(2-pyrrolidin-1-yl-ethoxy)-phenyl amide.**

To a solution of the hydroxy amine, (1-(2-hydroxyethyl)-pyrrolidine) [Aldrich], (1.87ml, 16mmol) in dimethylformamide was added portionwise sodium hydride [60% dispersion in oil, (544mg, 16mmol). After stirring at room temperature for 10 minutes a solution of  
30 the halonitrobenzene, (1-chloro-2-methoxy-4-nitro-benzene) [Avocado] (3g, 16mmol) in dimethylformamide (10ml) was added dropwise. The reaction mixture was left stirring at room temperature for 16hrs then concentrated. The residue was dissolved in ethyl acetate

(200ml) and washed with water (3 x 50ml). The organic phase was dried with magnesium sulphate, evaporated and the residue purified by flash chromatography on silica gel using dichloromethane - aq. ammonia - methanol as eluent to afford 1-[2-(2-methoxy-4-nitro-phenoxy)-ethyl]-pyrrolidine as a brown oil.

- 5  $^1\text{H}$  NMR ( $\text{CDCl}_3$ ):  $\delta$  1.82 (4H, m), 2.65 (4H, m), 3.01 (2H, t), 3.94 (3H, s), 4.24 (2H, t), 6.92 (1H, d), 7.74 (1H, d), and 7.89 (1H, dd); MS (AP +ve):  $m/z$  267  $[\text{M}+\text{H}]^+$ .

To a solution of the amine, 1-[2-(2-methoxy-4-nitro-phenoxy)-ethyl]-pyrrolidine (2.3g, 8.6mmol) in ethanol (100ml) was added 10% Pd/C (50mg). The mixture was stirred at  
10 room temperature under an atmosphere of hydrogen at atmospheric pressure for 16h, then filtered through celite and the filtrate concentrated to give the corresponding aniline; 3-methoxy-4-(2-pyrrolidin-1-yl-ethoxy)-phenylamine, as a brown solid.

- $^1\text{H}$  NMR ( $\text{CDCl}_3$ ):  $\delta$  1.80 (4H, m), 2.62 (4H, m), 2.89 (2H, t), 3.80 (3H, s), 4.06 (2h, t), 6.20 (1H, dd), 6.29 (1H, d) and 6.75 (1H, d); MS (AP +ve):  $m/z$  237  $[\text{M}+\text{H}]^+$ .

15

To the carboxylic acid, (4-biphenyl carboxylic acid) [Aldrich] (47.5mg, 0.24mmol) suspended in dichloromethane (1ml) was added oxalyl chloride [Aldrich] (0.06ml, 0.72mmol) followed by one drop of dimethylformamide. The reaction mixture was stirred at room temperature for 1 hour, concentrated, then co-evaporated three times with  
20 dichloromethane to give 4-phenylbenzoyl chloride. This was dissolved in dichloromethane (1ml) and added to a solution containing the amine, (3-methoxy-4-(2-pyrrolidin-1-yl-ethoxy)-phenylamine), (47 mg, 0.2mmol), triethylamine (0.14ml, 1mmol) and dichloromethane (1ml). The reaction mixture was stirred for 16 hours at room temperature, concentrated, re-dissolved in dichloromethane (10ml), filtered through an  
25 SAX column [Varian] (2g) and stirred with PS-isocyanate resin [Argonaut Technologies] (100mg, 0.38mmol) for 16 hours. The mixture was filtered, evaporated then purified by flash chromatography on silica gel using dichloromethane - aq. ammonia - methanol as eluent to afford the title compound as an oil.

- $^1\text{H}$  NMR ( $\text{CDCl}_3$ ):  $\delta$  1.88 (4H, m), 2.90 (4H, m), 3.08 (2H, t), 3.84 (3H, s), 4.21 (2H, t),  
30 6.83 (1H, d), 7.03 (1H, dd), 7.27-7.70 (8H, m) and 8.01 (2H, d); MS (AP+ve):  $m/z$  417  $[\text{M}+\text{H}]^+$ .

#### Example A54

Utilising the procedure of **Example A51** with 1-dimethylamino-2-propanol [Aldrich] in place of 1-(2-hydroxyethyl)-pyrrolidine.

**Example A56**

- 5 Correspondingly **Example A51** with 1-(2-hydroxyethyl)-piperidine [Aldrich].

**Example A58**

Correspondingly **Example A51** with 2-(hexamethyleneamino)-ethanol [Lancaster].

10 **Example A60**

Utilising the procedures of **Example A93** with 3-aminophenylboronic acid in place of 2-methoxyphenylboronic acid and **Example 51** with 2-dimethylaminoethanol in place of 1-(2-hydroxyethyl)pyrrolidine.

15 **Example A63**

Utilising the procedure of **Example A60** with 4-carboxyphenylboronic acid [Aldrich] in place of 3-aminophenylboronic acid.

**Example A70**

- 20 Correspondingly **Example A63** with (3,4-methylenedioxyphenyl)boronic acid [Aldrich].

**Example A72**

Utilising the procedure of **Example 51** with *N*-(2-phenyl)-ethyl-*N*-methyl-ethanolamine [J. Org. Chem. 1985, 50(22), 4359] in place of 1-(2-hydroxyethyl)-pyrrolidine.

25

**Example A74**

Correspondingly **Example 51** with 2-dimethylaminocyclohexanol [J. Chem. Soc. C (1969), (2), 248-52].

30

**Example A76**

Correspondingly **Example 51** with 2-(1,2,4,5-tetrahydro-benzo[*d*]azepin-3-yl)-ethanol [Patent US-394682]

**Example A78**

Correspondingly **Example 51** with 2-(3,4-dihydro-1*H*-isoquinolin-2-yl)-ethanol [Patent WO-9719926].

5

**Example A80**

Correspondingly **Example 51** with 2-(4-phenyl-piperazin-1-yl)-ethanol [J. Med. Chem. 1994, 37(13), 1964].

10 **Example A82**

Correspondingly **Example 51** with 1-methyl-3-pyrrolidinol [Aldrich].

**Example A84**

15 Utilising the procedures of **Example A93** with 4-methoxy-phenylboronic acid [Aldrich] in place of 2-methoxyphenylboronic acid and **Example A51** with 2-diethylaminoethanol in place of 1-(2-hydroxyethyl)pyrrolidine.

**Example A88**

20 Utilising the procedures of **Example A84** with 4-methoxy-3-pyridylboronic acid [Patent WO-9924440] in place of 4-methoxy-phenylboronic acid.

**Example A89**

Correspondingly **Example A88** with 2-methoxy-3-pyridylboronic acid [Patent WO-  
25 9910331].

**Example A90**

Correspondingly **Example A88** with benzo-[*b*]-furan-2-boronic acid [Aldrich].

30 **Example A91**

Correspondingly **Example A88** with thiophene-3-boronic acid [Aldrich].

**Example A92**

Correspondingly **Example A88** with indole-5-boronic acid [Frontier].

**Example A93**

5    **4'-Methyl-biphenyl-4-carboxylic acid [3-methoxy-4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-amide**

A mixture of 3-methoxy-4-(2-pyrrolidin-1-yl-ethoxy)-phenylamine [**Example A51**] (4.7mM 1.1g) and triethylamine (14mmol) was treated with 4-bromobenzoyl chloride [Aldrich] in dichloromethane (20ml) and kept at room temperature for 16 hours.

10    The solvent was evaporated and the crude product purified by chromatography on silica gel using dichloromethane - methanol - aq. ammonia to afford 4-bromo-N-[3-methoxy-4(2-pyrrolidin-1-yl-ethoxy)-phenyl]-benzamide as a white solid in 72% yield.

<sup>1</sup>H NMR (DMSO-d<sub>6</sub>): δ 7.91 (2H, dd), 7.73 (2H, dd), 7.50 (1H, d), 7.30 (1H, dd), 6.94 (1H, d), 4.02 (2H, t), 3.76 (3H, s), 2.77 (2H, t), 2.51 (4H, m under DMSO-d-5 signal) and 1.67 (4H, m); MS: (ES+ve) *m/z* 419, 421 [M+H]<sup>+</sup>

The amide, 4-bromo-N-[3-methoxy-4(2-pyrrolidin-1-yl-ethoxy)-phenyl]-benzamide (0.1mM 42mg), and 4-methyl-benzene boronic acid [Aldrich] (0.1mM 14mg) were  
20    refluxed for 16 hours in a mixture of benzene (8ml), ethanol (2ml) and 2M aqueous sodium carbonate (2ml) in the presence of tetrakis-(triphenylphosphine)-palladium[0] (5mg) under an argon atmosphere. The mixture was cooled, the upper layer decanted, and this solution purified by chromatography on silica gel using dichloromethane: methanol (10:1) followed by acetonitrile: satd. aqueous ammonia (25:1) to afford the  
25    title compound as a white solid.

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.92 (2H, dd), 7.68 (2H, dd), 7.50 (2H, dd), 7.26 (3H, dddd), 6.96 (1H, dd), 6.88 (1H, d), 4.13 (1H, t), 3.87 (3H, s), 2.92 (2H, t), 2.60 (4H, m), 2.41 (3H, s) and 1.80 (4H, m); MS: (AP-ve) *m/z* 429 [M-H]<sup>-</sup>; (AP+ve) *m/z* 431 [M+H]<sup>+</sup>.

30    **Example A100**

Utilising the procedure of **Example A93** with 4-(2,6-dimethoxypyrimidinyl)-boronic acid [Frontier] in place of 4-methyl-benzene boronic acid.



**Example A103**

Correspondingly **Example A93** with furan-3-boronic acid [Frontier].

5 **Example A104**

Correspondingly **Example A93** with mesityl-boronic acid [Frontier].

**Example A105**

Utilising the procedure of **Example A51** except employing chloroform in place of  
10 dichloromethane as a solvent and eluent and utilising 3-quinuclidinol [Aldrich] in place  
of 1-(2-hydroxyethylpyrrolidine)

**Example A107**

Utilising the procedure of **Example B37** except using piperidine in place of aniline.  
15

**Example B1**

Utilising the procedure of **Example A7** with 3-phenoxybenzoic acid [Aldrich] in place of  
2'-methyl-biphenyl-4-carboxylic acid.

20 **Example B2**

Correspondingly **Example B1** using 4-benzylbenzoic acid [Apin].

**Example B34**

Correspondingly **Example B1** using 3-benzylbenzoic acid [Patent WO-9828268].  
25

**Example B35**

Correspondingly **Example B1** using 4-phenoxybenzoic acid [Aldrich].

**Example B37**

30 **N-[-[3-Methoxy-4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-4-phenylamino-benzamide**  
Dry cesium carbonate (0.15mM, 49mg), (*S*)-BINAP [Aldrich] (0.015 mM, 9mg) and  
palladium acetate (0.0075mM, 2mg) were sonicated in anhydrous ethyleneglycol

dimethyl ether (15 ml) for 40 minutes under an argon atmosphere. This suspension was treated with 4-bromo-*N*-[3-methoxy-4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-benzamide [Example A93] (0.1mM, 42mg) and aniline (0.11mM, 10mg) then refluxed for 40 hours. The suspension was filtered through a hydrophobic membrane, concentrated, then  
5 purified on C18 R.P. silica using acetonitrile:water to afford the title compound as a white solid.

<sup>1</sup>H NMR (MeOH-d<sub>4</sub>): δ 7.96 (2H, dd) 7.92 (1H, d), 3.1 (2H, dd), 7.20 (1H, dd), 7.04 (1H, d), 4.28 (2H, t), 3.92 (3H, s), 3.78 (2H, m), 3.60 (2H, t), 3.58-3.13 (6H, m) and 2.26-1.47 (10H, m); MS: (ES+ve) *m/z* 424 [M+H]<sup>+</sup>

10

**Example C1**

Utilising the procedure of Example A7 with 2-methylbiphenyl-4-carboxylic acid [Patent WO-9606079] in place of 2'-methyl-biphenyl-4-carboxylic acid.

15 **Example C2**

Correspondingly Example C1 using 3-methoxybiphenyl-4-carboxylic acid [Patent WO-9534540].

**Example C3**

20 Correspondingly Example C1 using 3-methylbiphenyl-4-carboxylic acid [Patent WO-9534540].

**Example C4**

Correspondingly Example C1 using 4-phenylthiophene-2-carboxylic acid [Specs].

25

**Example C5**

Correspondingly Example C1 using 4-(3,5-dichlorophenoxy)-furan-2-carboxylic acid [Maybridge].

30 **Example C6**

Correspondingly Example C1 using 5-methyl-1-phenylpyrazole-4-carboxylic acid [Maybridge].

**Example C7**

Correspondingly **Example C1** using 6-phenyl-nicotinic acid [WO-0006085].

5 **Example C8**

Correspondingly **Example C1** using 3-chloro-biphenyl-4-carboxylic acid [Patent JP-09221476].

**Example C9**

10 Correspondingly **Example C1** using 5-(4-chlorophenyl)-2-trifluoromethyl-furan-3-carboxylic acid [Maybridge].

**Example C10**

15 Correspondingly **Example C1** using 2-(4-chlorophenyl)-3-(trifluoromethyl)-pyrazole-4-carboxylic acid [Maybridge].

**Example C11**

Correspondingly **Example C1** using 5-(2-pyridyl)-thiophene-2-carboxylic acid [Maybridge].

20

**Example C12**

Correspondingly **Example C1** using 5-(methyl-trifluoromethyl-2-*H*-pyrazol-3-yl)-thiophene-2-carboxylic acid [Maybridge].

25 **Example D1**

Utilising the procedure of **Example D5** with 3,4-dichloronitrobenzene [Aldrich] in place of 2,4-dichloronitrobenzene.

**Example D5**

30 **Biphenyl-4-carboxylic acid [2-chloro-4-(2-diisopropylamino-ethoxy)-phenyl]-amide.**  
To a three-neck flask (fitted with condenser, dropping funnel and thermometer) containing iron powder (938mg, 16.8mmol) mixed with a solution of ammonium chloride

(28mmol) in water (28ml), was added the amine [2-(3-chloro-4-nitro-phenoxy)-ethyl]-diisopropyl-amine [prepared by the method used to form 1-[2-(2-methoxy-4-nitro-phenoxy)-ethyl]-pyrrolidine in **Example A51** but with 2,4-dichloronitrobenzene [Aldrich] in place of 4-chloro-3-methoxynitrobenzene and 2-diisopropylaminoethanol in place of 1-(2-hydroxyethyl)-pyrrolidine], dropwise over 10 minutes. The reaction mixture was gently refluxed until t.l.c. analysis showed no starting material. The mixture was filtered while hot and the inorganic residues washed with methanol. The combined filtrates were partitioned between water (5ml) and ethyl acetate (3 x 10ml), the organic phase dried (MgSO<sub>4</sub>), filtered, and evaporated. The aqueous phase was treated with satd. aq. sodium bicarbonate (10ml), extracted with ethyl acetate (3 x 10ml), dried (MgSO<sub>4</sub>), and evaporated. Residues from both extractions were combined and purified by flash chromatography on silica gel using dichloromethane – methanol – aq. ammonia as eluent to afford 2-chloro-4-(2-diisopropylamino-ethoxy)-phenylamine as a brown oil.

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 1.02(12H, d), 2.77(2H, t), 3.03(2H, sept.), 3.72(2H, bs), 3.80(2H, t), 6.68(2H, m) and 6.85(1H, m); MS (AP+ve): *m/z* 271, 273 [M+H]<sup>+</sup>.

This material was used in place of 3-methoxy-4-(2-pyrrolidin-1-yl-ethoxy)-phenylamine in the procedure of **Example A51** to afford the title compound as clear oil.

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 1.26 (12H, d), 3.07 (2H, m), 3.35 (2H, m), 4.22 (2H, m), 6.89 (1H, dd), 7.01 (1H, m), 7.44 (3H, q), 7.62 (2H, d), 7.71 (2H, d), 7.97 (2H, d) and 8.34 (1H, d); MS (AP+ve): *m/z* 452, 454 [M+H]<sup>+</sup>.

#### **Example D9**

Utilising the procedure of **Example A51** with 2,4-difluoronitrobenzene [Aldrich] in place of 4-chloro-3-methoxynitrobenzene.

#### **Example D12 [WO-00/06146]**

Utilising the procedure of **Example A51** with 3,4-difluoronitrobenzene [Aldrich] in place of 4-chloro-3-methoxynitrobenzene.

#### **Example D16**

Utilising the procedure of **Example A51** with 2-methyl-4-fluoronitrobenzene [Aldrich] in place of 4-chloro-3-methoxynitrobenzene

#### **Example D20**

- 5 Utilising the procedure of **Example A51** with 3-methyl-4-fluoronitrobenzene [Aldrich] in place of 4-chloro-3-methoxynitrobenzene

#### **Example D24**

- 10 Utilising the procedure of **Example A51** with 3-acetyl-4-fluoronitrobenzene [Aldrich] in place of 4-chloro-3-methoxynitrobenzene

#### **Example D25**

**Biphenyl-4-carboxylic acid [4-(2-diisopropylamino-ethoxy)-2-formyl-5-methoxy-phenyl]-amide**

- 15 Biphenyl-4-carboxylic acid [4-(2-diisopropylamino-ethoxy)-3-methoxy-phenyl]-amide [Patent WO-9901127] (223 mg, 0.5 mmol) was treated with glyoxylic acid trihydrate (1ml), dichloromethane (5 ml) and methanesulphonic acid (0.5 ml). The mixture was stirred vigorously for 24 hours then treated with satd. aq. sodium bicarbonate (30ml) and extracted with dichloromethane (3 x 20ml). The combined organic phases were dried  
20 (MgSO<sub>4</sub>), filtered and evaporated, then subjected to flash chromatography on silica gel [chloroform – methanol – aqueous acetic acid] to obtain the title compound as the acetate salt, a white solid.

- <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 1.13 (12H, d), 2.04 (3H, s), 3.02 (2H, t), 3.20 (2H, hept.), 4.05 (3H, s), 4.10 (2H, t), 5.0 (1H, bs), 7.22 (1H, s), 7.40 (1H, t), 7.48 (2H, d), 7.65 (2H, d), 7.76  
25 (2H, d), 8.14 (2H, d), 8.72 (1H, s) and 9.34 (1H, s); MS (AP+ve): *m/z* 475 [M+H<sup>+</sup>].

#### **Example D26**

**Biphenyl-4-carboxylic acid [4-(2-diethylamino-ethoxy)-3-(1-hydroxy-ethyl)-phenyl]-amide**

- 30 To biphenyl-4-carboxylic acid [3-acetyl-4-(2-diethylamino-ethoxy)-phenyl]-amide [**Example D24**] (20mg, 0.05mmol) dissolved in a 1:1 mixture of tetrahydrofuran / ethanol (3ml), was added sodium borohydride [Aldrich] (6mg, 0.15mmol). The reaction mixture was stirred at ambient temperature for 16 hours. The solvent was evaporated and

the residue purified by flash chromatography on silica gel using dichloromethane - aq. ammonia - methanol as eluents, to afford the title compound as a white solid.

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 1.09 (6H, t), 1.49 (3H, d), 2.75 (4H, q), 2.95 (2H, t), 4.15 (2H, t), 5.01 (1H, q), 6.84 (1H, d), 7.45-7.67 (9H, m) and 7.95 (2H, d)

5 MS (AP+ve): *m/z* 433 [M+H]<sup>+</sup>.

#### Example D27

##### Biphenyl-4-carboxylic acid [4-(2-diethylamino-ethoxy)-3-ethyl-phenyl]-amide

To biphenyl-4-carboxylic acid [3-acetyl-4-(2-diethylamino-ethoxy)-phenyl]-amide  
10 [Example D24] (25mg, 0.06mmol) dissolved in dichloromethane (1.5ml), was added triethylsilane (0.5ml) and trifluoroacetic acid (0.25ml). The resulting yellow solution was stirred at room temperature for 120h. The solvents were evaporated and the residue purified by flash chromatography on silica gel using dichloromethane - aq. ammonia - methanol as eluents to afford the title compound as white solid.

15 <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 1.17 (6H, m), 2.64 (2H, q), 2.8 (4H, q), 3.06 (2H, t), 4.15 (2H, t), 6.82 (1H, d), 7.35-7.71 (9H, m) and 7.96 (2H, d)

MS (AP+ve): *m/z* 417 [M+H]<sup>+</sup>

#### Example D28 [WO9901127]

20 Utilising the procedure of Example A51 with 4-fluoronitrobenzene [Aldrich] in place of 4-chloro-3-methoxynitrobenzene, and 2-diisopropylaminoethanol in place of 1-(2-hydroxyethyl)-pyrrolidine

#### Example D30 [WO9901127]

25 Utilising the procedure of Example D28 with 2-dimethylaminoethanol [Aldrich] in place of 2-diisopropylaminoethanol.

#### Example D32 [WO9901127]

Utilising the procedure of Example D28 with 2-diethylaminoethanol [Aldrich] in place  
30 of 2-diisopropylaminoethanol

#### Example D38 [WO9901127]

Utilising the procedure of **Example A22** with 4-fluoronitrobenzene [Aldrich] in place of 4-chloro-3-methoxynitrobenzene, and 4-ethylphenylboronic acid in place of 4-methoxyphenylboronic acid

5 **Example D39 [WO9901127]**

Utilising the procedure of **Example A84** with 4-fluoronitrobenzene [Aldrich] in place of 4-chloro-3-methoxynitrobenzene, and 4-ethylphenylboronic acid in place of 4-methoxyphenylboronic acid.

10 **Example E1**

**Biphenyl-4-carboxylic acid [4-(2-diisopropylamino-ethoxy)-3-methoxy-phenyl]-methyl-amide.**

To 4-(2-diisopropylamino-ethoxy)-3-methoxy-phenylamine (1mmol) [**Example A7**] were added triethylorthoformate (8ml) and trifluoroacetic acid (0.15ml). The resulting solution was heated to 90°C for 4hr. The solution was evaporated then redissolved in ethanol and cooled to approximately -10°C. Sodium borohydride (190mg, 5mmol) was introduced portionwise over 10 minutes then the mixture allowed to warm to room temperature. The solution was stirred at room temperature for 16h, then acidified to pH 1 with 2M hydrochloric acid. The mixture was concentrated to approximately 10ml, then partitioned between ethyl acetate and water. The aqueous phase was adjusted to pH 14 using 2M aq sodium hydroxide solution, and extracted with dichloromethane (x3), dried (MgSO<sub>4</sub>), filtered and evaporated. The residue was purified by flash chromatography on silica gel using dichloromethane – aq. ammonia - methanol as eluent to afford [4-(2-diisopropylamino-ethoxy)-3-methoxy-phenyl]-methyl-amine as an oil.

25 <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 1.03 (12H, d), 2.80 (3H, s), 2.85 (2H, t), 3.02 (2H, q), 3.80 (3H, s), 3.86 (2H, t), 6.13 (1H, dd), 6.23 (1H, d) and 6.80 (1H, d); MS (AP+ve): m/z 281[M+H]<sup>+</sup>.

To 4-phenylbenzoic acid (0.2mmol) suspended in dichloromethane was added oxalyl chloride (0.6mmol) followed by dimethylformamide (1 drop). The reaction mixture was stirred for 1h, evaporated, co-evaporated (x3) with dichloromethane then redissolved in dichloromethane(1ml). A solution containing the amine [4-(2-diisopropylamino-ethoxy)-3-methoxy-phenyl]-methyl-amine (0.2mmol) and triethylamine (140mg, 1mmol) dissolved in dichloromethane (1ml) was added. This solution was stirred at ambient

temperature for 14 hours, evaporated, dissolved in dichloromethane (1ml) and treated with PS-isocyanate resin [Argonaut Technologies] (150mg). After a further 18h shaking at ambient temperature, the mixture was filtered, passed through an SAX column [Varian] (1g), evaporated, and the residue purified by chromatography on silica gel using dichloromethane – aq. ammonia - methanol as eluent to afford the title compound as an oil.

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 1.21 (12H, bd), 2.88-3.24 (4H, m), 3.32 (3H, s), 3.87 (3H, s), 4.11 (2H, m), 6.82-6.91 (3H, m) and 7.26-7.56 (9H, m); MS (AP+ve): *m/z* 476 [M+H]<sup>+</sup>.

#### 10 Example E5

Utilising the procedure of **Example E1** with triethyl orthoacetate [Aldrich] in place of triethyl orthoformate.

#### Example E12

#### 15 Biphenyl-4-carboxylic acid [2-chloro-4-(2-diisopropylamino-ethoxy)-5-methoxy-phenyl]-amide

Biphenyl-4-carboxylic acid [4-(2-diethylamino-ethoxy)-3-methoxy-phenyl]-methyl-amide [**Example E9**] (45mg, 0.1 mmol), was dissolved in chloroform (1ml) and treated with benzotriazole [Aldrich] (12 mg, 0.1 mmol) and *N*-chlorosuccinimide (13 mg, 0.11mmol). The mixture was stirred at ambient temperature for 16 hours then evaporated and subjected to flash chromatography on silica gel (dichloromethane – methanol – aqueous ammonia) to afford the title compound as an oil.

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 1.06 (6H, t), 2.63 (4H, q), 2.90 (2H, t), 3.39 (3H, s), 3.67 (3H, s), 4.03 (2H, t), 6.57 (1H, s), 6.84 (1H, s) and 7.31-7.53 (9H, m); MS (AP+ve): *m/z* 467, 469 [M+H]<sup>+</sup>.

#### Example E13

Utilising the procedures of **Example A93** with [4-(2-diethylamino-ethoxy)-3-methoxy-phenyl]-methyl-amine [**Example E9**] in place of 4-(2-diethylamino-ethoxy)-3-methoxy-phenylamine and 2-fluoromethylphenylboronic acid [Aldrich] in place of 4-methoxyphenylboronic acid and of **Example 51** with (*N*-diethyl)ethanolamine in place of 1-(2-hydroxyethyl)pyrrolidine.



**Example E14**

Utilising the procedure of **Example E13** with 2-methylphenylboronic [Aldrich] in place of 4-chlorophenylboronic acid.

5 **Example E16**

Correspondingly **Example E14** with 2-chloromethylphenylboronic acid [Aldrich].

**Example E17**

Correspondingly **Example E14** with 4-fluoromethylphenylboronic acid [Aldrich].

10

**Example E21**

Correspondingly **Example E14** with 4-chloromethylphenylboronic acid [Aldrich].

**Example E22**15 

Correspondingly **Example E14** with 4-ethylphenylboronic acid [Aldrich].

**Example E23**

Correspondingly **Example E14** with 4-*tert*butylphenylboronic acid [Aldrich].

20 **Example E24**

4-Biphenylcarboxylic acid [4-(2-diethylamino-ethoxy)-3-methoxy-phenyl]-methyl-amide [**Example E9**] (45mg, 0.1mmol), was dissolved in acetonitrile (1ml) and treated with *N*-fluoro-*N'*-chloromethyl-triethylenediamine-bis(tetrafluoroborate) (43mg, 0.12mmol) and heated to 80°C for 6 hours. The solvent was evaporated and the residue subjected to  
25 flash chromatography on silica gel (dichloromethane – methanol – aqueous ammonia) to afford the title compound as an oil.  
MS (AP+ve): *m/z* 451 [M+H]<sup>+</sup>.

**Example E25**30 

Utilising the procedure of **Example E1** with 4-(2-diisopropylamino-ethoxy)-3-methylphenylamine [**Example D20**] in place of 4-(2-diisopropylamino-ethoxy)-3-methoxyphenylamine and triethyl orthoacetate in place of triethyl orthoformate.

**Example F1**

Utilising the procedure of **Example A7** with 6-phenyl-nicotinic acid (Patent WO-0006085) in place of 2'-methyl-4-biphenylcarboxylic acid and *N*-dimethylethanolamine in place of 2-(diisopropylamino)ethanol.

**Example G1**

**Biphenyl-4-carboxylic acid [4-((*R*)-diethylamino-hydroxy-propoxy)-3-methoxy-phenyl]-amide**

4-Nitro-2-methoxyphenol [Aldrich] (845mg, 5mmol) was dissolved in DMF (25 ml) and treated with sodium hydride (60% oil dispersion, 200mg). When the effervescence ceased, the mixture was treated with (*R*)-*p*-nitrophenylsulphonyl glycidol [Aldrich] and warmed to 50°C with stirring. After 16 hours, the mixture was cooled, evaporated, partitioned between water (20ml) and dichloromethane (3 x 25ml), dried (MgSO<sub>4</sub>), filtered and evaporated. The residue was purified by flash chromatography on silica gel (hexane – ether) to give (*R*)-2-(2-methoxy-4-nitro-phenoxy-methyl)-oxirane as a pale brown solid in 80% yield.

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 2.79 (1H, dd), 2.95 (1H, dd), 3.41 (1H, dddd), 3.96 (3H, s), 4.06 (1H, dd), 4.43 (1H, dd), 6.98 (1H, d), 7.75 (1H, d) and 7.87 (1H, dd).

(*R*)-2-(2-Methoxy-4-nitro-phenoxy-methyl)-oxirane (0.5mmol, 113mg), in dichloromethane (3 ml) was treated with the amine (diethylamine) [Aldrich] (1.5 mmol, 110 mg) and titanium tetrakisopropoxide [Aldrich] (50ul). The solution was stirred at ambient temperature for 24 h, treated with water (1ml) and shaken vigorously for 10 minutes. The resulting suspension was passed through a hydromatrix cartridge [Varian ChemElut] (5ml) eluting with dichloromethane (10ml) to give (*R*)-diethylamino-(2-methoxy-4-nitro-phenoxy)-propan-2-ol as a yellow oil

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 1.07 (6H, t), 2.55-2.72 (7H, m), 3.94 (3H, s), 4.09-4.13 (3H, m), 6.97 (1H, d), 7.74 (1H, d) and 7.89 (1H, dd); MS (AP+ve): *m/z* 299 [M+H<sup>+</sup>].

This material was dissolved in ethanol (5ml) and treated with hydrogen chloride (2M in diethyl ether) 0.1 ml then 10% palladium on charcoal (20 mg) and hydrogenated at atmospheric pressure for 24 hours. The solution was purged with argon then filtered

through celite and evaporated to give (*R*)-(4-amino-2-methoxy-phenoxy)-diethylamino-propan-2-ol hydrochloride as a white crystalline solid.

<sup>1</sup>H NMR (CD<sub>3</sub>OD): δ 1.19 (6H, t), 3.36-3.45 (6H, m), 3.88 (s, 3H), 4.02-4.11 (2H, m), 4.03 (1H, m), 6.95-7.03 (2H, m) and 7.13 (1H, d).

5

A solution of this material in dichloromethane (2ml) was treated with triethylamine (2 mmol, 280ul) and triethylsilyl trifluoromethanesulphonate (1mmol, 264mg). After 30 minutes, 4-biphenylcarboxylic acid chloride [Example 1] (1mmol, 217mg) was introduced and the mixture stirred for 12 hours. The solvent was evaporated and the

10 residue dissolved in methanol (100ml) and treated with potassium carbonate (2g). After stirring for six hours, the suspension was evaporated, formed into a slurry with dichloromethane (20ml), filtered, the filtrate evaporated, and the residue purified by flash chromatography (dichloromethane – methanol - aq. ammonia) to give the title compound as a white solid.

15 <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 1.11 (6H, t), 2.61-2.78 (6H, m), 3.88 (3H, s), 3.5-4.5 (1H, vbs), 3.99-4.13 (3H, m), 6.92 (1H, d), 6.99 (1H, dd), 7.41-7.49 (3H, m), 7.56 (1H, d), 7.63 (2H, d), 7.69 (2H, d) and 7.97 (3H, d); MS (AP+ve): *m/z* 449 [M+H<sup>+</sup>].

#### Example G5

20 Utilising the procedure for the preparation of (*R*)-diethylamino-(2-methoxy-4-nitro-phenoxy)-propan-2-ol [Example G1] but replacing dichloromethane with 1,2-dichloroethane and diethylamine with diisopropylamine. In addition, the mixture of amine and epoxide was heated at 80°C for 12h rather than being kept at ambient temperature for 24 hours.

25

#### Example G8

Utilising the procedure of Example G1 but using (*S*)-*p*-nitrophenylsulphonyl-glycidol in place of (*R*)-*p*-nitrophenylsulphonyl-glycidol, and pyrrolidine in place of diethylamine.

#### 30 Example G22

Utilising the procedure of Example A51 but using 4-dimethylamino-1-butanol [ICN-RF] in place of 1-(2-hydroxyethyl)-pyrrolidine.

**Example H1****4-Cyclohexyl-N-[3-methoxy-4-(4-methyl-piperazin-1-yl)-phenyl]-benzamide**

A solution of 1-(2-methoxy-4-nitro-phenyl)-piperazine (Patent WO-9906382) (10mmol, 2.37g) in dichloromethane (50ml) was treated with di*tert*butyl dicarbonate (10mmol, 2.18g) with stirring. Vigorous evolution of gas occurred which ceased after 1 hour. The solution was then evaporated to a yellow solid 4-(2-methoxy-4-nitro-phenyl)-piperazine-1-carboxylic acid *tert*butyl ester.

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 1.50 (9H, s), 3.16 (4H, t), 3.61 (4H, t), 3.96 (3H, s), 6.88 (1H, d), 7.72 (1H, d) and 7.86 (1H, dd).

10

This material was dissolved in ethanol (50ml) and treated with 10% Pd on carbon (100mg). The suspension was hydrogenated at 1 atmosphere for 2 hours, then filtered through celite and evaporated to give 4-(4-amino-2-methoxy-phenyl)-piperazine-1-carboxylic acid *tert*butyl ester as a brown oil.

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 1.48 (9H, s), 2.86-2.91 (4H, t), 3.52-3.60 (4H, t), 3.81 (3H, s), 6.22-6.27 (2H, m) and 6.73 (1H, d).

This aniline (0.2mmol, 61 mg) was dissolved in dichloromethane (1ml) and treated successively with DIEA resin [Argonaut Technologies] (0.5 g) and 4-cyclohexylbenzoyl chloride [Example A36]. The mixture was shaken gently for 12 hours then filtered, evaporated and the residue purified by flash chromatography on silica gel (dichloromethane – methanol - aq. ammonia) to afford 4-(4-{[1-(4-cyclohexyl-phenyl)-methanoyl]-amino}-2-methoxy-phenyl)-piperazine-1-carboxylic acid *tert*butyl ester as a white crystalline solid

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 1.25-1.47 (5H, m), 1.54 (9H, s), 1.75-1.88 (5H, m), 2.56 (1H, m), 2.98 (4H, t), 3.61 (4H, t), 3.91 (3H, s), 6.87 (1H, d), 6.93 (1H, dd), 7.32 (2H, d), 7.54 (1H, s), 7.77, (1H, s) and 7.78 (2H, d); MS (AP+ve): *m/z* 493 [M+H<sup>+</sup>].

This material was dissolved in dichloromethane (5ml) and treated with anisole (1ml) and trifluoroacetic acid (5ml). After 2 hours the solution was evaporated, then co-evaporated twice from toluene. The residue was dissolved in dichloromethane (10ml), washed with satd. sodium bicarbonate (2ml), the organic phase dried (MgSO<sub>4</sub>), filtered and evaporated to a brown oil, 4-cyclohexyl-N-(3-methoxy-4-piperazin-1-yl-phenyl)-benzamide.


$^1\text{H}$  NMR ( $\text{CDCl}_3$ ):  $\delta$  1.22-1.87 (10, m), 2.57 (1, m), 3.04-3.12 (8H, m), 3.91 (3H, s), 6.95 (2H, bs), 7.32 (2H, d), 7.54 (1H, m), 7.77 (1H, s) and 7.78 (2H, d); MS (AP+ve):  $m/z$  394  $[\text{M}+\text{H}^+]$ .

- 5 This amine (0.1mmol, 39mg) was dissolved in ethanol (3ml) and treated with metaformaldehyde (100mg), Amberlyst cyanoborohydride resin [Novabiochem] (100mg), and acetic acid (50ul). The mixture was stirred at ambient temperature for three hours then filtered, evaporated and the residue purified by flash chromatography on silica gel (dichloromethane – methanol - aq. ammonia) to afford the title compound as a pale
- 10 brown oil. This was evaporated from dilute acetic acid to give the monoacetate salt hydrate.
- $^1\text{H}$  NMR ( $\text{CDCl}_3$ ):  $\delta$  1.22-1.45 (5H, m), 1.76-1.87 (5H, m), 2.02 (6H, 2xs), 2.56 (1H, m), 3.22-3.23 (4H, t), 3.29-3.30 (4H, t), 3.88 (3H, s), 6.86 (1H, d), 6.94 (1H, dd), 7.30 (1H, d), 7.59 (1H, d), 7.79 (2H, d), 7.98 (1H, s) and 8.54 (4H, bs);
- 15 MS (AP+ve):  $m/z$  408  $[\text{M}+\text{H}^+]$ .



























The following tables give Examples which illustrate but do not limit the invention in any way.



















**Table A**

Encompassing compounds of general formula (II), a subset of formula (I) where A = H and OMe, R3 = H, X = O, Y = CH<sub>2</sub>CH<sub>2</sub>, Z = a bond; R4 = Ph and R5 is either meta or para substituted on R4.











































Example No.	R5		meta / para	[M+H] <sup>+</sup>	Procedure
A1	Ph		p	447	A7
A2			p	453	A7
A3			p	437	A7
A4	Ph		m	447	A7
A5			p	448	A7
A6			p	489	A7
A7			p	461	A7
A8			p	453	A7





























A9			p	453	A7
A10			p	451	A7
A11			p	529	A7
A12			p	461	A7
A13			m	472	A7
A14			p	525	A7
A15			m	453	A7
A16			m	453	A7
A17			p	489	A7
A18			p	486	A7
A19			p	529	A7
A20			p	453	A7
A21			p	449	A7





























A22			p	477	A22
A23			p	515	A22
A24			p	462	A22
A25			p	553	A22
A26			p	497	A22
A27			p	497	A22
A28			p	461	A22
A29			p	493	A22
A30			p	515	A22












































A31			p	475	A22
A32			p	491	A22
A33			p	473	A22
A34			p	477	A22
A35	Ph		p	433	A51
A36			p	439	A51
A37	Ph		p	397	A51
A38			p	391	A51
A39			p	423	A51
A40	Ph		p	417	A51
A41	Ph		p	417	A51
A42			p	423	A51

A43	Ph		p	405	A51
A44			p	411	A51
A45	Ph		p	419	A51
A46			p	425	A51
A47	Ph		p	417	A51
A48			p	423	A51
A49	Ph		p	467	A51
A50			p	473	A51
A51	Ph		p	417	A51
A52			p	423	A51
A53			p	421	A22
A54	Ph		p	405	A51
A55			p	411	A51

A56	Ph		p	431	A51
A57			p	437	A51
A58	Ph		P	445	A51
A59			P	451	A51
A60			p	406	A60
A61			p	497	A63
A62			p	459	A63
A63			p	419	A63
A64			p	417	A63
A65			p	421	A63
A66			p	441	A63
A67			p	441	A63
A68			p	404	A63
A69			p	437	A63
A70			p	434	A63

A71			p	459	A63
A72	Ph		p	481	A51
A73			p	487	A51
A74	Ph		p	445	A51
A75			p	451	A51
A76	Ph		p	493	A51
A77			p	499	A51
A78	Ph		p	479	A51
A79			p	485	A51
A80	Ph		p	508	A51
A81			p	514	A51
A82	Ph		p	403	A51
A83			p	409	A51
A84			p	449	A84
A85			p	445	A88
A86			p	487	A88
A87			p	425	A88


A88			p	450	A88
A89			p	450	A88
A90			p	459	A88
A91			p	425	A88
A92			p	458	A88
A93			p	447	A93
A94			p	443	A93
A95			P	485	A93
A96			p	423	A93
A97			p	431	A93
A98			p	448	A93
A99			p	431	A93
A100			p	479	A93
A101			p	457	A93
A102			p	423	A93
A103			p	407	A93
A104			p	459	A93
A105	Ph		p	429	A105

A106			p	426	A107
A107			p	424	A107
A108			p	454	A107

**Table B**














Encompassing compounds of general formula (III), a subset of formula (1) where A = H and OMe, R1 = R2 = Me<sub>2</sub>, R3 = H, X = O, Y = CH<sub>2</sub>-CH<sub>2</sub>, Z = O, CH<sub>2</sub> or NH; R4 = Ph,

5 R5 is Ph and Z is either meta or para substituted on R4.


















(III)

Example No.	Z	meta / para		[M+H] <sup>+</sup>	Procedure
B1	O	m		463	B1
B2	CH <sub>2</sub>	p		461	B1
B3	O	m		229	A51
B4	CH <sub>2</sub>	p		4447	A51
B5	O	m		407	A51
B6	CH <sub>2</sub>	p		405	A51
B7	O	m		433	A51
B8	CH <sub>2</sub>	p		431	A51


B9	O	m		433	A51
B10	CH <sub>2</sub>	p		431	A51
B11	O	m		421	A51
B12	CH <sub>2</sub>	p		419	A51
B13	O	m		435	A51
B14	CH <sub>2</sub>	p		433	A51
B15	O	m		433	A51
B16	CH <sub>2</sub>	p		431	A51
B17	O	m		483	A51
B18	CH <sub>2</sub>	p		481	A51
B19	O	m		433	A51
B20	CH <sub>2</sub>	p		431	A51
B21	CH <sub>2</sub>	p		419	A51
B22	O	m		447	A51



B23	CH <sub>2</sub>	p		445	A51
B24	O	m		497	A51
B25	CH <sub>2</sub>	p		495	A51
B26	O	m		509	A51
B27	CH <sub>2</sub>	p		507	A51
B28	O	m		495	A51
B29	CH <sub>2</sub>	p		493	A51
B30	O	m		524	A51
B31	CH <sub>2</sub>	p		522	A51
B32	O	m		419	A51
B33	CH <sub>2</sub>	p		417	A51
B34	CH <sub>2</sub>	m		461	B1
B35	O	p		463	B1
B36	NH	p		462	B37
B37	NH	p		432	B37










**Table C**

Encompassing compounds of general formula (IV) a subset of formula (1) where A = H and OMe, R1 = R2 = Me<sub>2</sub>, R3 = H, X = O, Y = CH<sub>2</sub>-CH<sub>2</sub>; R4, R5 = substituted phenyl or heterocycle,




10

Example No.	Z	3 / 4 substitution w.r.t. C=O	R4	R5	[M+H] <sup>+</sup>	Method
C1	bond	4		Ph	461	C1
C2	bond	4		Ph	477	C1
C3	bond	4		Ph	461	C1
C4	bond	3		Ph	453	C1
C5	O	3			521, 523, 525	C1
C6	bond	3		Ph	451	C1
C7	bond	4		Ph	448	C1

C8	bond	4		Ph	481, 483	C1
C9	bond	3			539, 541	C1
C10	bond	3			539	C1
C11	bond	3			453	C1
C12	bond	3			525	C1












**Table D**













Encompassing compounds of general formula (V) a subset of formula (I) where R3 = H,  
 X = O, Y = CH<sub>2</sub>-CH<sub>2</sub>, Z = O, CH<sub>2</sub>, NH or a bond; R4 = Ph, R5 is Ph or cyclohexyl (Cy)  
 5 and Z is either meta or para substituted on R4.













10

Example No.	Z	R6	R7	R5	meta / para		[M+H] +	Method
D1	bond	Cl	H	Ph	p		452, 454	D1
D2	O	Cl	H	Ph	m		468, 470	D1
D3	CH <sub>2</sub>	Cl	H	Ph	p		466, 468	D1
D4	bond	Cl	H	Cy	p		458, 460	D1
D5	bond	H	Cl	Ph	p		452, 454	D5
D6	O	H	Cl	Ph	m		468, 470	D5


D7	CH <sub>2</sub>	H	Cl	Ph	p		466, 468	D5
D8	bond	H	Cl	Cy	p		458, 460	D5
D9	bond	F	H	Ph	p		435	D9
D10	CH <sub>2</sub>	F	H	Ph	p		449	D9
D11	bond	F	H	Ph	p		441	D9
D12	bond	H	F	Ph	p		435	D12
D13	O	H	F	Ph	m		451	D12
D14	CH <sub>2</sub>	H	F	Ph	p		449	D12
D15	bond	H	F	Cy	p		441	D12
D16	bond	Me	H	Ph	p		431	D16
D17	O	Me	H	Ph	m		447	D16

D18	CH <sub>2</sub>	Me	H	Ph	p		445	D16
D19	bond	Me	H	Cy	p		437	D16
D20	bond	H	Me	Ph	p		431	D20
D21	O	H	Me	Ph	m		447	D20
D22	CH <sub>2</sub>	H	Me	Ph	p		445	D20
D23	bond	H	Me	Cy	p		437	D20
D24	bond	COCH <sub>3</sub>	H	Ph	p		431	D24
D25	bond	OMe	CHO	Ph	p		475	D25
D26	bond	CH(OH)CH <sub>3</sub>	H	Ph	p		433	D26
D27	bond	Et	H	Ph	p		417	D27
D28	bond	H	H	Ph	p		417	D28
D29	O	H	H	Ph	m		433	D28

D30	bond	H	H	Ph	p		361	D30
D31	O	H	H	Ph	p		433	D28
D32	O	H	H	Ph	p		405	D32
D33	O	H	H	Ph	m		405	D32
D34	bond	H	H	Cy	p		423	D28
D35	bond	H	H	Cy	p		395	D32
D36	CH <sub>2</sub>	H	H	Ph	p		431	D28
D37	CH <sub>2</sub>	H	H	Ph	p		403	D32
D38	bond	H	H	p-EtPh	p		445	D38
D39	bond	H	H	p-EtPh	p		417	D39

**Table E**
















Encompassing compounds of general formula (VI) a subset of formula (1) where A = H, Cl, F and OMe, X = O, Y = CH<sub>2</sub>-CH<sub>2</sub>; R<sub>4</sub> = phenyl, R<sub>5</sub> = phenyl or cyclohexyl (Cy), Z = O, CH<sub>2</sub> or a bond



10


Example No.	Z	o/p	R <sub>3</sub>	R <sub>8</sub>	R <sub>9</sub>	R <sub>5</sub>		[M+H] +	Method
E1	bond	p	Me	H	MeO	Ph		461	E1
E2	O	m	Me	H	MeO	Ph		477	E1
E4	CH <sub>2</sub>	p	Me	H	MeO	Ph		475	E1
E5	bond	p	Me	H	MeO	Cy		467	E1
E6	bond	p	Et	H	MeO	Ph		447	E1
E7	bond	p	Et	H	MeO	Ph		445	E1
E8	bond	p	Me	H	MeO	Ph		431	E1
E9	bond	p	Me	H	MeO	Ph		433	E1
E10	bond	p	Et	H	MeO	Cy		453	E1
E11	bond	p	Et	H	MeO	Cy		451	E1
E12	bond	p	Me	Cl	MeO	Ph		468, 470	E12



E13	bond	P	Me	H	MeO	2-F-Ph		451	E13
E14	bond	p	Me	H	MeO	2-Me-Ph		447	E14
E15	bond	p	Me	H	MeO	2-MeO-Ph		463	E14
E16	bond	p	Me	H	MeO	2-Cl-Ph		468, 470	E14
E17	bond	p	Me	H	MeO	4-F-Ph		451	E14
E18	bond	p	Me	H	MeO	4-F3C-Ph		501	E14
E19	bond	p	Me	H	MeO	4-Me-Ph		447	E14
E20	bond	p	Me	H	MeO	4-MeO-Ph		463	E14
E21	bond	p	Me	H	MeO	4-Cl-Ph		468, 470	E14
E22	bond	p	Me	H	MeO	4-Et-Ph		461	E14
E23	bond	p	Me	H	MeO	4tBu-Ph		489	E14
E24	bond	p	Me	F	MeO	Ph		451	E24
E25	bond	p	Et	H	Me	Ph		459	E25
E26	bond	p	Et	H	Me	Cy		465	E25
E27	CH2	P	Et	H	Me	Ph		473	E25

# Table F

Encompassing compounds of general formula (VII) a subset of formula (1) where A = H and OMe, X = O, R4 = 3-pyridyl, R5 = phenyl, Z = a para bond




(VII)

Example No.		[M+H] <sup>+</sup>	Method
F1	R1 = R2 = Me	392	F1
F2		418	F1
F3		418	F1
F4		448	F1





























**Table G**

- Encompassing compounds of general formula (VIII) a subset of formula (I) where A = H and OMe, R3 = H, X = O; R4 = phenyl, Z = O, CH<sub>2</sub> or a bond and R5 = Ph or
- 5 cyclohexyl (Cy), Y is a chain of 3 or 4 carbon atoms optionally substituted by an hydroxyl group.




10

Example No.	Z	m/p	R5	XYN		[M+H] <sup>+</sup>	Method
G1	bond	p	Ph			449	G1
G2	bond	p	Ph			461	G1
G3	bond	p	Ph			476	G1
G4	bond	p	Ph			476	G1
G5	bond	p	Ph			465	G5
G6	bond	p	Ph			475	G1
G7	bond	p	Ph			475	G1
G8	bond	p	Cy			453	G8
G9	bond	p	Ph			447	G8

G10	bond	p	Cy			455	G8
G11	bond	p	Ph			449	G8
G12	bond	p	Cy			483	G5,G8
G13	bond	p	Ph			477	G5,G8
G14	bond	p	Cy			482	G8
G15	bond	p	Ph			476	G8
G16	bond	p	Cy			481	G8
G17	bond	p	Cy			481	G8
G18	bond	p	Ph			475	G8
G19	bond	p	Ph			475	G8
G20	bond	p	Ph			444	G8,G5
G21	bond	p	Ph			461	G8
G22	bond	P	Ph		NMe <sub>2</sub>	419	G22
G23	O	m	Ph		NMe <sub>2</sub>	435	G22
G24	CH <sub>2</sub>	p	Ph		NMe <sub>2</sub>	433	G22
G25	bond	p	Cy		NMe <sub>2</sub>	425	G22

## Table H

- Encompassing compounds of general formula (IX) a subset of formula (I) where A = H and OMe, R3 = H, X = N; R4 = phenyl, Z = a para substituted bond and R5 = Ph or cyclohexyl (Cy), Y and R2 form a piperazinyl ring between X and N.



10

Example No.	R5	R1	[M+H] <sup>+</sup>	Method
H1	Cy	Me	408	H1
H2	Cy	Et	436	H1
H3	Cy	iPr	422	H1

- 15 The activity of the compounds used in this invention may be assessed by competitive binding assays to 11CBy receptors, as follows:

### Radioligand Binding Studies

- 20 Radioligand binding assays were carried out on well washed membranes from HEK293 cells stably expressing 11CBy receptors. Membranes (5-15 mg protein) were incubated with [125I]-Melanin Concentrating Hormone (0.22 nM)(obtained from NEN) in the presence and absence of competing test compounds for 45 min at 37°C in a buffer (pH7.4), containing 50mM Tris and 0.2% BSA. Non-specific binding was defined using
- 25 0.1 mM Melanin Concentrating Hormone (obtained from Bachem). The test compounds were added at concentrations between 10M and 10pM in 10 concentration steps. Following incubation, the reaction was stopped by filtration through GF/B filters and

washed with 4 x 1ml of ice-cold 50mM Tris buffer. Microscint 20 (Packard) was added to the filters and the radioactivity measured using a Packard TopCount.

Bound cpm in the presence of test compound was expressed as a fraction of the bound  
5 cpm in the absence of test compound and plotted against the concentration of compound.  
From this an IC50 was determined from which the pKi was calculated.


The most potent compounds of the present invention have pKi values in the range of 7.1  
to 7.8 For example:

10	<b>Example</b>	<b>pKi range</b>
	A48	7.5-7.8
	B2	7.1-7.4
	C8	7.1-7.4
	D15	7.5-7.8
15	E9	7.5-7.8
	F4	7.1-7.4
	G1	7.1-7.4
	H1	7.1-7.4

20


## CLAIMS

1. A method of treating the Disorders which comprises administering to a mammal suffering from one or more of the Disorders an effective amount of a compound of  
 5 formula (I), or a pharmaceutically acceptable salt or solvate thereof, in which:



- each A is independently hydrogen, a C<sub>1-6</sub> alkyl optionally substituted by hydroxyl, C<sub>1-6</sub> alkoxy, C<sub>1-6</sub> alkenyl or C<sub>1-6</sub> acyl group or a halogen atom or hydroxyl, CN or CF<sub>3</sub> group;  
 R<sub>3</sub> is hydrogen, methyl or ethyl;  
 10 R<sub>4</sub> is an optionally substituted aromatic carbocyclic or heterocyclic ring;  
 Z is an O or S atom, or an NH or CH<sub>2</sub> group, or a single bond, at the 3 or 4 position of R<sub>4</sub> relative to the carbonyl group;  
 R<sub>5</sub> is an optionally substituted aromatic carbocyclic or heterocyclic ring, or an optionally substituted, saturated or unsaturated, carbocyclic or heterocyclic ring;

15



20

- (a) where X is an O or S atom;  
 Y is a linear or branched C<sub>2-4</sub> alkylene group, optionally substituted by a hydroxyl group, or is a C<sub>5-6</sub> cycloalkylene group,  
 25 R<sub>1</sub> and R<sub>2</sub> are independently a linear or branched C<sub>1-6</sub> alkyl, phenyl C<sub>1-6</sub> alkyl group; or  
 (b) where X is an O or S atom;  
 Y is a linear or branched C<sub>2-4</sub> alkylene group, optionally substituted by a hydroxyl group,  
 R<sub>1</sub> and R<sub>2</sub> are linked to form a 5, 6 or 7-membered ring optionally containing one or more further heteroatom selected from O, S or N, where N or C ring atoms are optionally

substituted by Ra, -CO-Ra, -CO-NH-Ra, or CO-O-Ra, where Ra is a linear or branched C<sub>1-6</sub> alkyl or aryl group; and the 5, 6 or 7-membered ring is optionally fused to an optionally substituted benzene ring, or a ring atom of the 5, 6 or 7-membered ring is optionally linked by a single bond or methylene group to Y; or

5 (c) where X is an O or S atom,

Y is a C<sub>2-4</sub> alkylene group, R1 is a C<sub>2-4</sub> alkylene group linked to Y to form a 5 or 6 membered ring and R2 is a linear or branched C<sub>1-6</sub> alkyl group; or

(d) where X is a N atom,

10 Y is a C<sub>2-4</sub> alkylene group, R1 is a C<sub>2-4</sub> alkylene group linked to X to form a 5 or 6 membered ring and R2 is a linear or branched C<sub>1-6</sub> alkyl group.

2. A compound of formula (I) as defined in claim 1, or a salt or solvate thereof, in which R3 is methyl or ethyl.

15 3. A compound according to claim 2, which is any one of the compounds set out in Table E herein.

4. A compound of formula (I) as defined in claim 1 or a salt or solvate thereof, excluding the compounds:

20 *N*-[4-[2-[bis(1-methylethyl)amino]ethoxy]-2-fluorophenyl]-[1,1'-biphenyl]-4-carboxamide,

*N*-[4-[2-[bis(1-methylethyl)amino]ethoxy]phenyl]-[1,1'-biphenyl]-4-carboxamide,

biphenyl-4-carboxylic acid [4-(2-diisopropylamino-ethoxy)-phenyl]-amide,

*N*-[4-(2-diisopropylamino-ethoxy)-phenyl]-4-phenoxy-benzamide,

25 *N*-[4-(2-diethylamino-ethoxy)-phenyl]-4-phenoxy-benzamide,

*N*-[4-(2-diisopropylamino-ethoxy)-phenyl]-3-phenoxy-benzamide

*N*-[4-(2-diethylamino-ethoxy)-phenyl]-3-phenoxy-benzamide,

4-cyclohexyl-*N*-[4-(2-diisopropylamino-ethoxy)-phenyl]-benzamide,

4-cyclohexyl-*N*-[4-(2-diethylamino-ethoxy)-phenyl]-benzamide,

30 4-benzyl-*N*-[4-(2-diisopropylamino-ethoxy)-phenyl]-benzamide,

4-benzyl-*N*-[4-(2-diethylamino-ethoxy)-phenyl]-benzamide,

4'-ethyl-biphenyl-4-carboxylic acid [4-(2-diisopropylamino-ethoxy)-phenyl]-amide,



and 4'-ethyl-biphenyl-4-carboxylic acid [4-(2-diethylamino-ethoxy)-phenyl]-amide.


5. A process for the preparation of a compound of formula (I), or a salt or solvate thereof, as defined in claim 2, which process comprises the reaction of a compound of

5 formula (X)



where R5, Z, and R4 are as defined for formula (I) in claim 1, and L is a leaving group

10 with a compound of formula (XI)



(XI)

15 wherein Q and A are as defined in formula (I) in claim 1 and R3 is methyl or ethyl.

6. A process for the preparation of a compound of formula (I), or a salt or solvate thereof, as defined in claim 1, which process comprises the reaction of a compound of formula (X) wherein R5, Z, and R4 are as defined for formula (I) in claim 1 with a  
20 compound of formula (XI) wherein Q, A, and R3 are as defined in claim 1, with the proviso that a process for the preparation of:

*N*-[4-[2-[bis(1-methylethyl)amino]ethoxy]-2-fluorophenyl]-[1,1'-biphenyl]-4-carboxamide,

*N*-[4-[2-[bis(1-methylethyl)amino]ethoxy]phenyl]-[1,1'-biphenyl]-4-carboxamide,

25 biphenyl-4-carboxylic acid [4-(2-diisopropylamino-ethoxy)-phenyl]-amide,

*N*-[4-(2-diisopropylamino-ethoxy)-phenyl]-4-phenoxy-benzamide,

*N*-[4-(2-diethylamino-ethoxy)-phenyl]-4-phenoxy-benzamide,

*N*-[4-(2-diisopropylamino-ethoxy)-phenyl]-3-phenoxy-benzamide,

*N*-[4-(2-diethylamino-ethoxy)-phenyl]-3-phenoxy-benzamide,

30 4-cyclohexyl-*N*-[4-(2-diisopropylamino-ethoxy)-phenyl]-benzamide,

4-cyclohexyl-N-[4-(2-diethylamino-ethoxy)-phenyl]-benzamide,  
4-benzyl-N-[4-(2-diisopropylamino-ethoxy)-phenyl]-benzamide,  
4-benzyl-N-[4-(2-diethylamino-ethoxy)-phenyl]-benzamide,  
4'-ethyl-biphenyl-4-carboxylic acid [4-(2-diisopropylamino-ethoxy)-phenyl]-amide,  
5 and 4'-ethyl-biphenyl-4-carboxylic acid [4-(2-diethylamino-ethoxy)-phenyl]-amide  
is excluded.

7. A pharmaceutical composition for use in the treatment and/or prophylaxis of one  
or more of the Disorders which comprises a compound of this invention, or a  
10 pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable  
carrier.

8. A method of treatment and/or prophylaxis of one or more of the Disorders  
comprising administering to the sufferer in need thereof an effective or prophylactic  
15 amount of a compound of this invention, or a pharmaceutically acceptable salt or solvate  
thereof.

9. Use of a compound of this invention, or a pharmaceutically acceptable salt or  
solvate thereof, for the manufacture of a medicament for the treatment and/or prophylaxis  
20 of one or more of the Disorders.

10. Use of a novel compound of this invention, or a pharmaceutically acceptable salt  
or solvate, thereof as a therapeutic agent, in particular for the treatment and/or  
prophylaxis of one or more of the Disorders.

25

11. A method for the treatment of diabetes, major depression, manic depression,  
anxiety, schizophrenia and sleep disorders, in human or non-human mammals which  
method comprises the administration of a therapeutically effective amount of an  
antagonist to the human 11CB $\gamma$  receptor.

30

# INTERNATIONAL SEARCH REPORT

International Application No.  
P 01/08637

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D295/08 C07D295/14 C07D295/12 C07C233/75 C07C235/84  
A61K31/165 A61K31/395 A61K31/381 A61P5/48 C07C235/42  
C07C235/48 C07C237/40 C07D271/06 C07D231/12 C07D213/56

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D C07C A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, BEILSTEIN Data, CHEM ABS Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	WO 00 47558 A (YOSHITOMI) 17 August 2000 (2000-08-17) pages 168, 267 - 269, 271, 272; claims	1-11
X	WO 99 01127 A (SMITHKLINE BEECHAM) 14 January 1999 (1999-01-14) cited in the application examples 4-11, 38	1-11
X	claims	1, 7-11
X	WO 00 06146 A (SMITHKLINE BEECHAM) 10 February 2000 (2000-02-10) cited in the application claims; examples	1, 7-11

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*B\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

\*G\* document member of the same patent family

Date of the actual completion of the international search

1 November 2001

Date of mailing of the international search report

12/11/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HW Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Zervas, B

# INTERNATIONAL SEARCH REPORT

International Application No

EP 01/08637

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D213/64 C07D333/24 C07D241/12 C07D317/60 C07D207/09  
C07D211/26 C07D223/04 C07C323/62 C07C317/44

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*G\* document member of the same patent family

Date of the actual completion of the international search

1 November 2001

Date of mailing of the international search report

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Zervas, B

## INTERNATIONAL SEARCH REPORT

I International Application No  
EP 01/08637

Patent document cited in search report		Publication date		Patent family member(s)		Publication date
WO 0047558	A	17-08-2000	AU	2460600 A		29-08-2000
			WO	0047558 A1		17-08-2000
WO 9901127	A	14-01-1999	AU	735208 B2		05-07-2001
			AU	8381398 A		25-01-1999
			BR	9810758 A		15-08-2000
			CN	1261795 T		02-08-2000
			EP	1001766 A1		24-05-2000
			HU	0004232 A2		28-04-2001
			NO	996490 A		27-12-1999
			TR	200000015 T2		21-08-2000
			WO	9901127 A1		14-01-1999
			ZA	9805542 A		07-04-1999
WO 0006146	A	10-02-2000	AU	5239299 A		21-02-2000
			BR	9912406 A		24-04-2001
			CN	1310621 T		29-08-2001
			EP	1100485 A1		23-05-2001
			NO	20010446 A		26-01-2001
			WO	0006146 A1		10-02-2000